Enhanced DNA dendrimers and methods of use thereof

The combination of carrier polynucleotide and DNA dendrimer, combining targeted moieties and adaptor molecules, solves the problem of delivery and expression of therapeutic nucleic acid molecules in cells, and achieves the effect of safe delivery and optimized expression.

CN119095602APending Publication Date: 2024-12-06CODE BIOTHERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380021051.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-10
Filing Date
2023-02-09
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver therapeutic nucleic acid molecules to the target cell nucleus, and it is difficult to maintain their safety and optimize their expression.

Method used

Using a composition containing carrier polynucleotides and DNA dendrimers, the targeting moiety binds to cell surface molecules, and uses adaptor molecules and support molecules to assist in the passage of carrier polynucleotides into the cell nucleus to achieve safe delivery and optimization of nucleic acids. Express.

Benefits of technology

The safe delivery of therapeutic nucleic acid molecules to the target cell nucleus is achieved, avoiding degradation, optimizing expression, and improving transfection efficiency and stability of nucleic acids in the cell.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004985493210000201
    Figure BDA0004985493210000201
  • Figure BDA0004985493210000211
    Figure BDA0004985493210000211
  • Figure BDA0004985493210000212
    Figure BDA0004985493210000212
Patent Text Reader

Abstract

Provided herein are compositions comprising a DNA dendrimer linked to a targeting moiety and a carrier polynucleotide, in some embodiments, the carrier polynucleotide being directly linked to the DNA dendrimer. In some embodiments, the carrier polynucleotide is linked to the DNA dendrimer by a linker molecule. In some embodiments, the carrier polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one molecule of interest, and having a topological structure selected from the group consisting of intact cyclic polynucleotides, nicked cyclic polynucleotides, linear polynucleotides having closed 5 'and 3' ends, linear polynucleotides having open 5 'and 3' ends, and linear polynucleotides having one open end and one closed end. In some embodiments, the carrier polynucleotides herein optionally comprise one or more of a DNA target sequence (DTS), a nuclear localization signal sequence (NLS), or a DNA dendrimer binding sequence.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 308,776, filed on February 10, 2022, which is hereby incorporated by reference in its entirety. Technical Field

[0003] Embodiments of the invention relate to DNA dendrimers and other molecules linked to or encoding targeting molecules, cargo molecules, adapter molecules, support molecules, or combinations thereof, and methods of using and producing the same. Background Art

[0004] In many research, diagnosis and treatment applications, the target of action of molecules such as reporter probes, small molecule drugs, peptides or nucleic acids is intracellular. For nucleic acids that need to be transcribed and / or translated in target cells, nucleic acids must be safely transported to the nucleus. However, the cell type selected by molecular targeting, the intracellular delivery to the cytosol and the subsequent transportation to the required intracellular compartment such as the nucleus represent challenging goals. In addition, the therapeutic nucleic acid carrier must remain safe and not degraded, and must be expressed in the nucleus with neither too limited nor too much amount. Therefore, it is necessary to have such a composition, which can reliably deliver molecules such as therapeutic nucleic acids to the nucleus of target cells without degradation, and has the ability to optimize expression. The present disclosure solves this demand and other needs. Summary of the invention

[0005] Provided herein are compositions comprising DNA dendrimers connected to targeting moieties and cargo polynucleotides. In some embodiments, the cargo polynucleotide is directly connected to the DNA dendrimer. In some embodiments, the cargo polynucleotide is connected to the DNA dendrimer via an adapter molecule. In some embodiments, the cargo polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one target molecule, and has a topological structure selected from the following: a complete circular polynucleotide, a nicked circular polynucleotide, a linear polynucleotide with closed 5' and 3' ends, a linear polynucleotide with open 5' and 3' ends, and a linear polynucleotide with one open end and one closed end. In some embodiments, the cargo polynucleotide herein optionally comprises one or more of a DNA target sequence (DTS), a nuclear localization signal sequence (NLS), or both.

[0006] In some embodiments, the carrier polynucleotide comprises a DNA dendrimer binding sequence (DBS). In some embodiments, the DBS connects the carrier polynucleotide to the DNA dendrimer. In some embodiments, the adapter molecule comprises a DBS and a carrier binding region. In some embodiments, the DBS connects the adapter molecule to the DNA dendrimer. In some embodiments, the carrier binding region connects the adapter molecule to the carrier polynucleotide. In some embodiments, the adapter molecule further comprises one or more of the following: a purification region, a DTS, an NLS, a spacer, a cell penetrating peptide (CPP) sequence, a cleavage site, a flexible linker, or a combination thereof.

[0007] In some embodiments, any of the compositions provided herein may further comprise a support molecule. In some embodiments, the support molecule may be associated with a DNA dendrimer. In some embodiments, the support molecule is attached to a DNA dendrimer. In some embodiments, the support molecule compresses the size of the cargo polynucleotide, the DNA dendrimer, or both.

[0008] Also provided herein are compositions comprising a cargo polynucleotide, a support molecule, and a DNA dendrimer linked to a targeting moiety, wherein the cargo polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one target molecule and has a topology selected from the group consisting of a complete circular nucleotide, a nicked circular nucleotide, a linear nucleotide with closed 5' and 3' ends, a linear nucleotide with open 5' and 3' ends, and a linear nucleotide with one open end and one closed end. In some embodiments, the cargo polynucleotide is in a complete circular topology and is not linked to a DNA dendrimer.

[0009] Also provided herein is a plasmid comprising a plasmid backbone comprising at least two restriction sites, at least one promoter and at least one coding sequence encoding at least one target molecule, wherein the plasmid is capable of forming a cargo polynucleotide having various topological structures. In some embodiments, the various topological structures are selected from complete cyclic nucleotides, nicked cyclic nucleotides, linear nucleotides with closed 5' and 3' ends, linear nucleotides with open 5' and 3' ends, and linear nucleotides with one open end and one closed end.

[0010] In some embodiments, a method for delivering a target molecule to the nucleus of a target cell is provided, the method comprising contacting the target cell with any composition described herein, wherein the targeting moiety binds to the target cell to allow the composition to enter the target cell, and wherein the carrier polynucleotide is capable of entering the nucleus of the target cell. In some embodiments, a method for treating a disease is provided, the method comprising administering any composition described herein to a subject to treat the disease, wherein the targeting moiety binds to the target cell to allow the composition to enter the target cell, and wherein the carrier polynucleotide is capable of entering the nucleus of the target cell. In some embodiments, a method for making a carrier polynucleotide is provided, the method comprising adding at least one promoter and at least one coding sequence encoding at least one target molecule to a plasmid backbone to form any plasmid described herein, and then optionally contacting the plasmid with one or more restriction enzymes. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 Depicted are diagrams showing a plasmid map and the individual topological structures into which the plasmid can be altered by contacting or not contacting certain restriction enzymes with the plasmid.

[0012] Figure 2 The percentage of GFP fluorescence for various polynucleotide topologies is depicted.

[0013] Figure 3 Depicted are graphs showing the number of GFP-positive cells per unit area for various polynucleotide topologies.

[0014] Figure 4 Depicted are the relative mean fluorescence of polynucleotides containing a DNA targeting sequence (DTS) compared to polynucleotides without a DTS in CHO-K1 cells.

[0015] Figure 5 Depicted are the relative mean fluorescence of polynucleotides containing a DNA targeting sequence (DTS) compared to polynucleotides without a DTS in A427 cells.

[0016] Figure 6 Depicted are the relative mean fluorescence of polynucleotides containing a DNA targeting sequence (DTS) compared to polynucleotides without a DTS in C2C12 cells.

[0017] Figure 7 Depicted are the relative integrated fluorescence of polynucleotides containing a DNA targeting sequence (DTS) compared to polynucleotides without a DTS in C2C12 cells.

[0018] Figure 8Depicted are the relative peak fluorescence of polynucleotides containing a DNA targeting sequence (DTS) compared to polynucleotides without a DTS in C2C12 cells. DETAILED DESCRIPTION

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein may be used in practice or testing, suitable methods and materials are described herein. In the event of a conflict, this specification, including definitions, will prevail. In addition, materials, methods and examples are illustrative only and are not intended to be restrictive. From the specific embodiments of the present invention and the claims, other features and advantages of the embodiments provided herein will be apparent.

[0020] Techniques and procedures for recombinant manipulations, including nucleic acid and peptide synthesis, are generally performed according to conventional methods in the art and in various general references (e.g., Sambrook et al., 2001, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., eds., 2005, Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY; and Gerhardt et al., eds., 1994, Methods for General and Molecular Bacteriology, American Society for Microbiology, Washington, DC), which are provided throughout this document.

[0021] The term "about" or "approximately" means the numerical value of the number with which it is used plus or minus 10%. Thus, about 50% means within the range of 45%-55%. Unless the context clearly indicates otherwise, the singular forms "a", "an", and "the" include plural referents.

[0022] As used herein, the terms "comprising," "having," and "including" and their cognates mean "including but not limited to." Although various compositions, methods, and apparatus are described as "comprising" various components or steps (interpreted to mean "including but not limited to"), the compositions, methods, and apparatus may also "consist essentially of" or "consist of" the various components and steps.

[0023] The term "antibody" as used herein refers to an immunoglobulin molecule that can specifically bind to a specific epitope on an antigen. Antibodies can be complete immunoglobulins from natural sources or from recombinant sources, and can be immunoreactive portions of complete immunoglobulins. Antibodies that can be used in the present invention can exist in various forms, including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies ("intrabodies"), Fv, Fab and F(ab)2, as well as single-chain antibodies (scFv), camelid antibodies and humanized antibodies (Harlow et al., 1999, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, Antibodies: A Laboratory Manual, Cold Spring Harbor, NY; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85: 5879-5883; Bird et al., 1988, Science 242: 423-426).

[0024] As used herein, "complementarity" refers to the broad concept of subunit sequence complementarity between two nucleic acids (e.g., two DNA molecules). When a nucleotide position in the two molecules is occupied by nucleotides that are normally capable of base pairing with each other, the nucleic acids are considered to be complementary to each other at that position. Thus, two nucleic acids are substantially complementary to each other (e.g., A:T and G:C nucleotide pairs) when at least about 50%, preferably at least about 60%, and more preferably at least about 80% of the corresponding positions in each molecule are occupied by nucleotides that are normally base pairing with each other.

[0025] As used herein, "DNA-based vector" refers to a delivery system comprising a deoxyribonucleic acid molecule. A non-limiting example of a DNA-based vector is a DNA dendrimer. Other DNA-based vectors include double-stranded DNA, single-stranded DNA, and single-stranded hairpin DNA or polymers thereof.

[0026] As used herein, "DNA dendrimer" or "dendrimer" refers to a polynucleotide matrix that exhibits branching, formed by the sequential or generative addition of branching layers to or from a core molecule (such as an initiating monomer).

[0027] As used herein, an "initiator monomer" is a polynucleotide compound used to nucleate the formation of a dendrimer.

[0028] As used herein, "extension monomers" are polynucleotide compounds that can bind to initiating monomers and / or to each other during dendritic polymer assembly. Extension monomers form layers of dendritic polymers. The first layer of a dendritic polymer is the layer of extension monomers that is closest to the initiating monomers. The outer layer is the layer that is farthest from the initiating monomers and forms the surface of the dendritic polymer. Extension monomers are also referred to in the art as matrix monomers, matrix extension monomers, and matrix polynucleotide monomers.

[0029] The term "substitution" or "substituted" or "mutation" or "mutant" as used herein refers to the change, deletion or insertion of one or more amino acids or nucleotides in a polypeptide or polynucleotide sequence to produce a variant of the sequence.

[0030] The term "polynucleotide" or "nucleic acid molecule" means a molecule comprising a chain of nucleotides covalently linked by a sugar-phosphate backbone or other equivalent covalent chemical means. Double-stranded and single-stranded DNA and RNA are non-limiting examples of polynucleotides.

[0031] The term "polypeptide" or "protein" means a molecule comprising at least two amino acid residues linked by a peptide bond to form a polypeptide. In some embodiments, the term "peptide" may also be used.

[0032] As used herein, the term "variant" refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide by one or more modifications, including substitutions, insertions, or deletions.

[0033] Conventional notation is used herein to describe polynucleotide sequences: the left end of a single-stranded polynucleotide sequence is the 5' end; the left direction of a double-stranded polynucleotide sequence is referred to as the 5' direction.

[0034] As used herein, the term "promoter / regulatory sequence" refers to a nucleic acid sequence that controls or promotes the expression of a gene product operably linked to a promoter / regulatory factor sequence. In some cases, the sequence may be a core promoter sequence, in other cases, the sequence may also include a

[0035] The term "inducible" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced substantially only in the presence of an inducer that corresponds to (e.g., binds to) the promoter.

[0036] As used herein, "targeting moiety" refers to a molecule that binds to a molecule present on the cell surface of a target cell.

[0037] As used herein, "targeted DNA-based vector" and "DNA-based vector comprising a targeting moiety" refer to a composition comprising a DNA-based vector and a targeting moiety. The targeting moiety can be linked to the DNA-based vector directly or through a linker. Alternatively, the targeting moiety can be linked to another molecule, such as a vehicle molecule or a secondary non-nucleic acid vector in the composition. The DNA-based vector is targeted by virtue of being present in the same composition as the targeted vehicle or targeted secondary vector.

[0038] As used herein, the term "vector" includes nucleic acids that can infect, transfect, transiently or permanently transduce cells. It will be appreciated that a vector can be a naked nucleic acid, or a nucleic acid complexed with a protein or lipid. Vectors include, but are not limited to, replicons (such as RNA replicons, bacteriophages), to which DNA fragments can be attached and replicated. Therefore, vectors include, but are not limited to, RNA, autonomous self-replicating circular or linear DNA or RNA (i.e., "plasmids"), and include expression plasmids and non-expression plasmids. When recombinant microorganisms or cell cultures are described as having "expression vectors", this includes extrachromosomal circular and linear DNA and DNA that has been integrated into one or more host chromosomes. When a vector is maintained by a host cell, the vector can be stably replicated by the cell as an autonomous structure during mitosis, or be integrated into the host's genome.

[0039] As used herein, "promoter" means a molecule of synthetic or natural origin that can confer, activate or enhance the expression of a nucleic acid in a cell. A promoter may contain one or more specific transcriptional regulatory sequences to further enhance its expression and / or change its spatial expression and / or temporal expression. A promoter may also include a distal enhancer or repressor element, which may be located as far as several thousand base pairs from the transcription start site. Such promoter-enhancers may be modified, for example, but not limited to, tissue specificity or transduction efficiency. Promoters may be derived from sources including viruses, bacteria, fungi, plants, insects, and animals. A promoter may constitutively regulate the expression of a gene component, or relative to the cell, tissue, or organ in which expression occurs, or relative to the developmental stage in which expression occurs, or in response to external stimuli such as physiological stress, pathogens, metal ions, or inducers to differentially regulate the expression of a gene component.

[0040] As used herein, the term "topology" refers to different structural arrangements of any vector, plasmid or polynucleotide disclosed herein. For example, a polynucleotide can have a circular topology, such as a plasmid, in which the polynucleotide does not have a 5' or 3' end. The polynucleotide disclosed herein can also have a linear topology, in which the polynucleotide has a 5' and 3' end. The polynucleotide with a linear topology can have one or two covalently closed polynucleotide ends. In some embodiments, certain restriction enzymes can covalently close DNA ends, such as telomerase N (Tel N).

[0041] Composition

[0042] A. DNA-based vectors

[0043] In some embodiments, the compositions disclosed herein include DNA-based vectors. DNA-based vectors include, but are not limited to, DNA dendrimers, double-stranded linear DNA, single-stranded linear DNA, and single-stranded hairpin DNA, which are formulated as single-molecule structures or include several units (e.g., polymers) in a cross-linked conformation. In some embodiments, the composition includes DNA dendrimers. DNA dendrimers are spherical particles (typically about 130 to about 150 nm in diameter, but they can be designed to other sizes) of flexible branches formed by mutually hybridized DNA monomers. Each DNA monomer consists of two polynucleotide chains that share a central region of complementary sequences, where the two chains hybridize to each other, leaving four terminal single-stranded polynucleotide portions. These terminal sequences are complementary between them; therefore, they can hybridize (in layers) with the terminal sequences of other DNA monomers. Optionally, the DNA dendrimers include covalently cross-linked DNA chains.

[0044] DNA dendrimers are commercially available. In addition, the structural design and assembly of DNA dendrimers are generally known in the art. See, for example, U.S. Patent Nos. 5,175,270 and 6,274,723, each of which is incorporated herein by reference in its entirety. The initiating monomer constitutes the approximate center of the dendrimer, depending on the type of branching in the dendrimer. The three-dimensional assembly of extension monomers around the initiating monomer forms the interior volume of the dendrimer. Finally, the outer layer of extension monomers forms the surface of the dendrimer. Thus, the assembly of the dendrimer produces a three-dimensional shape, typically but not exclusively, a roughly spherical shape containing a layer of extension monomers. The outer layer contains many binding sites.

[0045] More specifically, DNA dendrimers can be prepared by a protocol having the following features. (i) The starting material is a double-stranded duplex of DNA with 5′ and 3′ single-stranded overhangs, or “binding arms,” attached to the duplex backbone (e.g., four binding arms total), called “initiator monomers,” which describe their role in dendrimer assembly. The 5′ and 3′ binding arms of each initiator monomer anneal to complementary binding arms of similar composition and morphology on an “extension monomer.” (ii) A subset of the four binding arms on each extension monomer are complementary to the binding arms on the initiator monomer. The non-complementary binding arms of the extension monomers are inactive for annealing to the initiator monomer. Typically, four extension monomers can be annealed with the initiator monomer to produce a monolayer or layer of dendrimers in solution. (iii) To add another layer of extension monomers to the dendrimer, similar but distinguishable extension monomers are typically added, each of which has a subset of its four binding arms that are complementary to the binding arms on the dendrimer. Thus, one layer of dendrimer can be converted stepwise to two layers of dendrimer, and so on, until the desired size of the dendrimer is reached. Typically, three or four layer dendrimers are used.

[0046] After assembly, DNA dendrimers can be cross-linked to maintain and stabilize the structure of the dendrimer. Cross-linked hybridization regions between monomers (i.e., inter-monomer crosslinks) or between monomers and nucleic acids carrying detectable labels and between backbone portions (intra-monomer crosslinks) can stabilize the structure of polynucleotide dendrimers. Similarly, any hybridization region of any DNA-based vector can be cross-linked to stabilize the vector. Individual vector units can also be cross-linked into multi-molecular vectors. Such cross-linking chemistry is well known in the art. See, for example, Cimino et al., Annu. Rev. Biochem. 54: 1151-1193 (1985); Shi et al., Biochemistry 25: 5895-5902 (1986); and Cimino et al., Biochemistry 25: 3013-3020 (1986). See also, U.S. Patent No. 4,196,281. Non-limiting examples of suitable cross-linking agents include: psoralen (including but not limited to 8-methoxypsoralen and angelicin), mitomycin C, daunomycin, ethidium diazide, cisplatin, transplatin, carboplatin, 8-methoxypsoralen, nitrogen mustard, oxaliplatin, and carbodiimide compounds, etc.

[0047] The polynucleotide chains used in dendrimer monomers or other DNA-based vectors can be prepared using standard techniques for synthesizing nucleic acids. These techniques can be biological or chemical. The techniques and procedures are generally performed according to conventional methods in the art and various general references (e.g., Sambrook et al., 2001, supra; Ausubel et al., eds., 2005, supra and Gerhardt et al., eds., 1994, Methods for General and Molecular Bacteriology, American Society for Microbiology, Washington, DC).

[0048] In some embodiments, polynucleotides are chemically synthesized using methods known in the art. See, e.g., Gait, 1985, Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, England. In another embodiment, polynucleotides are enzymatically synthesized using the polymerase chain reaction (PCR). One PCR method suitable for producing single-stranded polynucleotides is multiple cycles of PCR using a single primer, thereby amplifying a single strand. Nucleic acids can be purified prior to use by any suitable means well known in the art. For example, nucleic acids can be purified by reverse phase or ion exchange HPLC, size exclusion chromatography, or gel electrophoresis. Those skilled in the art will recognize that the purification method will depend in part on the size of the nucleic acid to be purified.

[0049] The outer layer of the DNA dendrimer can have at least two types of binding arms. These binding arms can be used to attach one or more types of moieties. In some embodiments, the DNA dendrimer of the composition can be bound or attached to a targeting moiety, a cargo, a support molecule, etc.

[0050] In some embodiments, the DNA-based vector is associated with a secondary vector that can be used as a scaffold for the DNA-based vector. Examples of such secondary vectors include, but are not limited to, liposomes, non-DNA dendrimers, polymer carriers, microbubbles, paramagnetic and ferromagnetic particles, self-assembling polymers, polymer vesicles, filamentous micelles (filomicelles), albumin particles, lipoproteins, etc. Self-assembling polymers are polymers formed by the self-assembly of unimolecular building blocks (building blocks). These building blocks can be amphiphilic copolymers, which contain hydrophilic components (such as, but not limited to, polyethyleneimine or polyethylene glycol) and hydrophobic components (such as, but not limited to, aliphatic polyesters), forming a core-shell structure. These structures that are not maintained by direct conjugation or cross-linking of building blocks are called micelles, and their morphology can vary, for example, from spherical micelles ("polymer vesicles") to elongated or filamentous rods ("filamentous micelles"). The size of these structures can also vary in the nanometer to micrometer size range. Once formed by self-assembly, these structures can alternatively be further chemically cross-linked to increase their stability. Hydrophobic cargoes can be embedded in the hydrophobic regions of the carrier, while hydrophilic cargoes can be integrated into the inner aqueous core or the outer hydrophilic corona.

[0051] In some embodiments, the DNA-based vector is attached to the surface of the secondary vector. In some embodiments, the DNA-based vector is not attached, but is associated with the secondary vector by virtue of being in the same composition. In some embodiments, the vehicle and targeting moiety can be attached to the DNA-based vector, or to the scaffold vector, using methods described herein and known in the art.

[0052] B. Targeting Moiety

[0053] In some embodiments, a DNA-based vector is directed to a specific cell by attaching a targeting moiety to a vector, a secondary vector, and / or a carrier. In some embodiments, a targeting moiety is attached to a DNA-based vector. In some embodiments, a targeting moiety is attached to a secondary vector. The targeting moiety can be an antibody, a naturally occurring ligand of a receptor or a functional derivative thereof, a vitamin, a hormone, a small molecule mimetic of a naturally occurring ligand, a peptide, a polypeptide, a peptide mimetic, a carbohydrate, a lipid, an FN3 domain, an aptamer, a nucleic acid, a toxin, a component of a microorganism, or any other molecule, provided that it specifically binds to a cell surface molecule and induces endocytosis of the bound moiety.

[0054] Without being bound by any particular theory, the targeting moiety can specifically bind to a molecule on the cell surface of the target cell. The targeting moiety can bind to a cell surface molecule that, in some embodiments, can induce endocytosis of a DNA-based vector. Non-limiting examples of cell surface molecules that can be targeted include cell surface proteins, carbohydrates, and lipids. Cell surface molecules that can be targeted include molecules associated with classical endocytosis and molecules associated with non-classical endocytosis.

[0055] In some embodiments, the target cell surface molecule is a cell adhesion molecule (CAM). Cell adhesion molecules that can be used for the present invention include, but are not limited to, neural specific adhesion molecules (e.g., NCAM) and systemic intercellular adhesion molecules. Systemic CAMs include intercellular adhesion molecules (e.g., ICAM-1, ICAM-2, ICAM-3), platelet-endothelial cell adhesion molecules (PECAM), activated leukocyte cell adhesion molecules (ALCAM), B-lymphocyte cell adhesion molecules (BL-CAM), vascular cell adhesion molecules (VCAM), mucosal vascular addressin cell adhesion molecules (MAdCAM), CD44, LFA-2 (CD2), LFA-3 (CD58), basigin (CD147), etc. In some embodiments, the cell surface molecule is CD71.

[0056] In some embodiments, the targeting moiety is an antibody that specifically binds to a target cell surface molecule. In some embodiments, the antibody is selected from polyclonal antibodies, monoclonal antibodies, humanized antibodies, synthetic antibodies, heavy chain antibodies, and biologically active fragments of antibodies, wherein the biologically active fragment is a Fab fragment, a F(ab')2 fragment, a sc-Fv fragment.

[0057] When the antibody used as the targeting moiety in the compositions and methods of the present invention is a polyclonal antibody (IgG), antibodies are produced by inoculating suitable animals with targeted cell surface molecules. The antibodies specifically bound to the cell surface molecules produced in the inoculated animal are then separated from the liquid obtained from the animal. Antibodies can be produced in several non-human mammals such as, but not limited to, goats, sheep, horses, camels, rabbits and donkeys in this way. Methods for producing polyclonal antibodies are well known in the art and are described in, for example, Harlow et al. (1988, In: Antibodies, A Laboratory Manual, Cold Spring Harbor, NY).

[0058] Monoclonal antibodies or fragments thereof directed to full-length targeting cell surface molecules can be prepared using any well-known monoclonal antibody preparation procedures, such as, for example, those described in Harlow et al. (1988, In: Antibodies, A Laboratory Manual, Cold Spring Harbor, NY) and Tuszynski et al. (1988, Blood, 72: 109-115). Human monoclonal antibodies can be prepared by the method described in U.S. Patent Publication 2003 / 0224490. Monoclonal antibodies directed to the antigen are produced from mice immunized with the antigen using the standard procedures cited herein. Nucleic acids encoding monoclonal antibodies obtained using the procedures described herein can be cloned and sequenced using techniques available in the art, and are described, for example, in Wright et al. (1992, Critical Rev. in Immunol. 12 (3, 4): 125-168) and the references cited therein.

[0059] In order to prepare a targeted DNA-based vector, such as a DNA dendrimer, a targeting moiety can be connected to a DNA-based vector, or a secondary vector or vehicle, which is connected or associated with a composition comprising a DNA-based vector. A single targeting moiety can be connected to a DNA-based vector or a secondary vector. Alternatively, multiple (e.g., two or more) targeting moieties are connected to a DNA-based vector, a secondary vector or a vehicle. When multiple targeting moieties are connected to a vector or a vehicle, the moieties can target the same cell surface molecule or can target different cell surface molecules. If different cell surface molecules are targeted, these molecules can be associated with the same endocytic pathway or different endocytic pathways. The targeting moiety can also not be associated with an endocytic pathway. If different cell surface molecules are targeted, the cell surface molecules can be present on the same cell type or can be present on different cell types.

[0060] The connection can be non-covalent or covalent. The targeting moiety can be directly connected to one or more polynucleotide chains comprising the DNA-based vector. Alternatively, the targeting moiety is connected to a linker molecule, which in turn is connected to the DNA-based vector. In some embodiments, where the DNA-based vector is a DNA dendrimer, the linker molecule is an oligonucleotide comprising a sequence that is substantially complementary to a sequence present in one of the binding arms on the surface of the DNA dendrimer. Therefore, by hybridization of the oligonucleotide to the binding arm, the targeting moiety is indirectly and non-covalently connected to the DNA dendrimer. This method is also applicable to other DNA-based vectors. Optionally, the hybridized oligonucleotide is also cross-linked to the DNA dendrimer. Cross-linking chemistry is disclosed elsewhere herein. When not cross-linked, the hybridization between the DNA dendrimer and the oligonucleotide connected to the targeting moiety should be long enough to exist under the conditions of use. Determining the binding free energy of nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp. 123-133; Freier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc. 109:3783-3785; Chavali et al., 2005, Bioinformatics 21(20):3918-3925).

[0061] In some embodiments, the linker is an IgG Fc specific secondary antibody connected to a DNA-based carrier. In some embodiments, the antibody is specifically bound to the Fc portion of an IgG primary antibody, such as a targeting moiety or an inserted antibody. The secondary antibody is preferably specific to the species origin of the primary antibody. For example, if the targeting moiety is a human IgG antibody, the secondary antibody is an anti-human IgG. On the other hand, the secondary antibody recognizes the epitope of the entire primary antibody, rather than just the Fc moiety. Alternatively, the linker is an Fc gamma receptor specifically bound to the Fc moiety of an IgG antibody. In any of these, the carrier can be easily connected to any targeting moiety as an IgG antibody.

[0062] Non-covalent attachment includes, but is not limited to, affinity binding pairs, such as biotin-streptavidin and immunoaffinity, which have sufficiently high affinity to maintain attachment during use, and are well known in the art. The art is also full of conjugated chemistries that can be used to covalently attach a target moiety directly or via a joint to a DNA-based vector, secondary vector, or vehicle. Art-recognized covalent coupling techniques are disclosed in, for example, U.S. Patents 5,416,016, 6,335,435, 6,528,631, 6,861,514, and 6,919,439, which are incorporated herein by reference in their entirety. Other conjugated chemical structures are disclosed in U.S. Patent Publication No. 20040249178, which is incorporated herein by reference in its entirety. Other conjugation chemistries include: p-hydroxybenzoic acid linker (Chang-Po et al., 2002, Bioconjugate Chem. 13(3):525-529); native ligation (Stetsenko et al., 2000, J Org. Chem. 65:4900-4908); disulfide bridge conjugates (Oehlke et al., 2002, Eur J. Biochem. 269:4025-4032 and Rogers et al., 2004, Nuc Acids Res. 32(22)6595-6604); maleimide linker (Zhu et al., 1993, Antisense Res Dev. 3:265-275); thioester linker (Ede et al., 1994, Bioconjug Chem. 5:373-378); Diels-Alder cycloaddition (Marchán et al., 2006. Nuc Acids Res. 34 (3): e24, electronic publication February 14, 2006); U.S. Pat. No. 6,656,730, etc. For a review of peptide-oligonucleotide conjugation chemistry, see also Tung et al., 2000, Bioconjugate Chem. 11: 605-618; Zatsepin et al., 2005, Curr Pharm Des. 11 (28): 3639-3654; and Juliano, 2005, Curr Opin Mol. Ther. 7 (2): 132-136.

[0063] C.Cargo

[0064] The compositions provided herein may also include a carrier. In some embodiments, the carrier is directly or indirectly attached to the DNA dendrimer. The carrier attached to the DNA dendrimer is associated with the DNA dendrimer via a linker or other types of molecules (adapters) and the like. One, two or more different carriers can be delivered by a targeted DNA-based vector. The carriers that can be delivered according to the compositions disclosed herein include, but are not limited to, a variety of agents, including but not limited to therapeutic agents, imaging agents, monitoring agents, chemotherapeutic agents, anti-carcinogens, anti-angiogenic agents, tumor inhibitors, antimicrobial agents, enzyme replacement agents, gene expression regulators, and expression constructs containing nucleic acids encoding therapeutic proteins or therapeutic nucleic acids. In some embodiments, the carrier may be an exogenous substance or an endogenous substance. The carrier includes any molecule that induces an effect in the cell, including any protein, nucleic acid, small molecule, carbohydrate or lipid. The carrier may be a peptide, protein (including enzymes, antibodies and peptide hormones), ligands of the cytoskeleton, nucleic acids, small molecules, non-peptide hormones, etc. The nucleic acid and carrier polynucleotide that can be delivered by the method of the present invention include synthetic and natural nucleic acid materials, including DNA, RNA, transposon DNA, antisense nucleic acid, dsRNA, siRNA, transcription RNA, messenger RNA, ribosomal RNA, small nucleolar RNA, microRNA, ribozyme, plasmid and expression construct. When the carrier is or comprises nucleic acid, the nucleic acid can be an entity separated from the carrier based on DNA. In these embodiments, the carrier based on DNA itself is not a carrier.

[0065] In some embodiments, the carrier is a polynucleotide comprising at least one promoter and at least one coding sequence encoding at least one target molecule. For example, the carrier polynucleotide can comprise a promoter and two or more coding sequences encoding different target molecules, or one promoter for each coding sequence present. In some embodiments, one or more promoters are tissue-specific promoters that transcribe or translate the at least one target molecule only when the composition comprising the carrier polynucleotide is present in a target cell that matches the tissue-specific promoter.

[0066] In some embodiments, the target molecule is a gene product, such as an enzyme, protein, receptor, etc. In some embodiments, the cargo polynucleotide encodes two or more target molecules. In some embodiments, at least one target molecule is a detectable molecule, such as, but not limited to, a labeled protein that can be detected via bioluminescence, fluorescence, a radiant signal, or a combination thereof. In some embodiments, such target molecules can be used for biodistribution studies and other quantitative and / or real-time assessments.

[0067] In some embodiments, the carrier polynucleotide can have one or more structures or topological structures. For example, the carrier polynucleotide can exist as a complete circular, double-stranded DNA or RNA, without free 5' or 3' ends. In some embodiments, the carrier polynucleotide is a plasmid. In some embodiments, the carrier polynucleotide can be a circular polynucleotide with a nick, a linear polynucleotide with a closed 5' and 3' end, a linear polynucleotide with an open 5' and 3' end, and a linear polynucleotide with an open end and a closed end. In some embodiments, the circular polynucleotide with a nick is a complete circular, double-stranded DNA or RNA with at least one break in the single strand of DNA or RNA. In some embodiments, the nick is attributable to the effect of a nicking restriction enzyme. In some embodiments, the linear polynucleotide has a limited 5' and 3' end, wherein either end or both ends are optionally closed via a covalent bond.

[0068] Different topologies or structures can be used for different attachments to the DNA dendrimers.

[0069] Provided herein is a plasmid comprising a plasmid backbone, the plasmid backbone comprising at least two restriction sites, at least one promoter and at least one coding sequence encoding at least one target molecule, wherein the plasmid can form a carrier polynucleotide with various topological structures (such as those provided herein). For example, a gene cassette comprising a promoter sequence and a coding sequence encoding at least one target molecule can be inserted into the plasmid backbone. The resulting plasmid can have a complete circular topological structure, and if such a topological structure is desired, no further steps are required. However, if different topological structures are desired, the plasmid can be contacted with one or more restriction enzymes to break one or two nucleotide chains of the plasmid and produce a nicked circular polynucleotide, a linear polynucleotide with closed 5' and 3' ends, a linear polynucleotide with open 5' and 3' ends, or a linear polynucleotide with an open end and a closed end. In some embodiments, telomerase N (Tel N) is used to form the closed end on the linear polynucleotide.

[0070] In some embodiments, the carrier polynucleotide is transported to the nucleus of the cell. In some embodiments, the carrier polynucleotide may also include one or more of a DNA targeting sequence (DTS) or a nuclear localization signal (NLS). DTS and NLS are independently short amino acid sequences that target proteins and related nucleic acids to be introduced into the nucleus. For example, the NLS that can be encoded by the carrier polynucleotide has an amino acid sequence of YPDEVKRKKKP (SEQ ID NO: 1) or SLLESPFDKPDEVKRKKKPPTSHQSDATAEDDSSSKKK (SEQ ID NO: 2). These are non-limiting examples of NLS sequences and any NLS can be used. In some embodiments, at least one DTS, at least one NLS or both may be located anywhere within the carrier polynucleotide or may be located anywhere relative to the carrier polynucleotide. For example, DTS, NLS or both may be located upstream or downstream of the at least one promoter of the carrier polynucleotide. In such molecules, a polypeptide is connected to a carrier polynucleotide.

[0071] In some embodiments, one or more DTS or NLS sequences can be attached or connected to a carrier polynucleotide, rather than being located within the carrier polynucleotide. In some embodiments, one or more DTS or NLS sequences can be included in any adapter molecule described herein, wherein the adapter molecule is connected to the carrier polynucleotide. In some embodiments, one or more DTS or NLS sequences can be directly connected to a carrier polynucleotide without associating with a corresponding adapter molecule. In some embodiments, a DTS or NLS sequence can be attached to a carrier polynucleotide via a modified nucleotide. For example, a DTS or NLS sequence can be attached to a nicked circular carrier polynucleotide at a nicking site, optionally with a modified nucleotide first inserted at the nicking site.

[0072] In some embodiments, the cargo (including the cargo polynucleotides described herein) can be directly attached to the DNA dendrimer by any covalent or non-covalent interaction or bond described herein, such as a hydrogen bond. Thus, in some embodiments, the cargo polynucleotide comprises a DNA dendrimer binding sequence (DBS) that attaches the cargo polynucleotide to the DNA dendrimer. In some embodiments, the DBS comprises a nucleic acid sequence complementary to a nucleic acid sequence on the DNA dendrimer. For example, the DBS comprises a nucleic acid sequence complementary to at least one binding arm of the DNA dendrimer. In some embodiments, the DBS binds to the DNA dendrimer via hydrogen bonds. In some embodiments, the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO: 3). In some embodiments, the DBS sequence further comprises a polythymine sequence at the 5' or 3' end of the sequence. For example, in some embodiments, the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTTT (SEQ ID NO: 4). In some embodiments, the DBS comprises a nucleic acid sequence of CCTCAGCTTGTACTCTAGT TGTTACCTCTAATGCTGGACCTCAGC (SEQ ID NO: 22). In some embodiments, the DBS comprises a nucleic acid sequence of CCTCAGCACCCTACAGAGTAA CCTAGATTGATCAAACACCTCAGC (SEQ ID NO: 23). These are non-limiting examples of DBS molecules, and any DBS sequence that is complementary to the dendrimer arm can be used.

[0073] D. Adaptor molecules

[0074] The cargo can also be linked to the DNA dendrimer via an adapter molecule provided herein. In some embodiments, the adapter molecule comprises a DNA dendrimer binding sequence (DBS) that links the adapter molecule to the DNA dendrimer and a cargo binding region that links to the cargo (e.g., a cargo polynucleotide provided herein).

[0075] In some embodiments, the DBS comprises a nucleic acid sequence that is complementary to a nucleic acid sequence on the DNA dendrimer. For example, the DBS comprises a nucleic acid sequence that is complementary to at least one binding arm of a DNA dendrimer. In some embodiments, the DBS binds to the DNA dendrimer via hydrogen bonding. In some embodiments, the DBS comprises any DBS sequence disclosed herein. In some embodiments, any DBS sequence that is complementary to a dendrimer arm can be used.

[0076] In some embodiments, the carrier binding region can be connected to the carrier polynucleotide by a joint known in the art. For example, the carrier binding region can include a nucleic acid sequence complementary to at least a portion of the carrier polynucleotide, and / or be connected to the carrier by DNA connection. In another example, the carrier binding region can be connected to the carrier polynucleotide by chemical coupling (such as but not limited to click chemistry or EDC cross-linking). In some embodiments, the carrier binding region includes at least one nucleotide with an amine, an azide or other reactive group. In some embodiments, the carrier binding region includes at least one cysteine ​​residue.

[0077] The adapter molecule may also include other regions or features. In some embodiments, such regions or features may be located between the DBS and the cargo binding region, but may also be located within the adapter molecule in any order.

[0078] In some embodiments, the adapter molecule further comprises at least one purification region. In some embodiments, the purification region comprises at least one purification tag or affinity tag. The purification tag or affinity tag can be any such chemical or amino acid tag known in the art, such as a polyhistidine tag, such as but not limited to His6, His 12, etc.

[0079] In some embodiments, the adapter molecule further comprises a DTS, NLS, or both as provided herein. In some embodiments, the DTS and NLS regions are located between the DBS and the cargo binding region. In some embodiments, the NLS has an amino acid sequence of YPDEVKRKKKP (SEQ ID NO: 1) or SLLESPFDKPDEVKRKKKPPTSHQSDATAEDDSSSKKK (SEQ ID NO: 2). In some embodiments, the DTS or NLS region further comprises at least one spacer located before or after the STS or NLS region. If there are two spacers, they are directly located before and after the DTS, NLS, or both. Spacers are generally known in the art and comprise a series of flexible or semi-flexible amino acids or molecules. In some embodiments, one or more spacers comprise a polyglycine sequence, optionally with alanine and / or serine residues. In some embodiments, one or more spacers have an amino acid sequence of GGGG (SEQ ID NO: 5). In some embodiments, one or more spacers comprise polyethylene glycol (PEG), propylene glycol alginate (PGA), PEG-polylactic acid (PLA), polylactic acid-co-glycolic acid (PGLA), or any combination thereof. In some embodiments, one or more spacers comprise a saturated or unsaturated hydrocarbon chain comprising 3-6 carbons that may be optionally substituted.

[0080] In some embodiments, the adapter molecule further comprises a cell penetrating peptide sequence (CPP). CPP is a group of short peptides that have the ability to increase membrane transduction and can be used to assist in the transport of molecules through the cell membrane (for review, see Xu et al., 2019, J Control Release, 309: 106-124). A variety of CPPs may be included in the adapter molecule to help the composition based on DNA dendrimers enter the target cell or target cell nucleus. For example, in some embodiments, CPP has an amino acid sequence of QPRRRPRRKKRG (SEQ ID NO: 6). In some embodiments, CPP is located between the DBS and the carrier binding region.

[0081] In some embodiments, the cargo can be separated from the DNA dendrimer. Therefore, in some embodiments, the adapter molecule also comprises one or more cleavage sites. The cleavage site can be located anywhere between the DBS and the cargo binding region. In some embodiments, the cleavage site is located adjacent to or almost adjacent to the DBS. For example, in some embodiments, the cleavage site is a valine-citrulline / p-aminobenzylcarbamate (val-cit) cleavable linker. The val-cit linker is known in the art and is used for drug conjugation to release the cargo from the targeting portion. Other cleavable linkers known in the art may also be included, such as ribozyme self-cleavage cleavage sites, or adjustable pH-sensitive linkers (see, for example, Choy et al., Bioconjugate Chem. (2016) 27 (3): 824-830).

[0082] In some embodiments, the adapter molecule further comprises at least one flexible linker. In some embodiments, the flexible linker is located between the DNS and the cargo binding region. In some embodiments, at least one flexible linker is or comprises polyethylene glycol (PEG), propylene glycol alginate (PGA), PEG-polylactic acid (PLA), polylactic acid-co-glycolic acid (PGLA), (GG)n, (GGGGS)n (SEQ ID NO: 7), (GGGGA)n (SEQ ID NO: 27) or any combination thereof, wherein each n is independently 1-5.

[0083] The adapter molecules provided herein can have none, some or all of the optional elements disclosed herein. For example, in addition to the DBS and cargo binding region, the adapter molecule can comprise one or more purification regions, DTS, NLS, CPP, spacer, cleavage site, flexible linker or any combination thereof. Non-limiting examples of adapter molecules are listed below.

[0084]

[0085]

[0086] In some embodiments, provided compositions comprise a targeting moiety disclosed herein and a cargo, wherein the targeting moiety and the cargo are linked by an adapter molecule comprising at least one DTS. In some embodiments, the targeting moiety / adapter molecule having a DTS / cargo composition does not comprise a DNA dendrimer.

[0087] In some embodiments, the composition comprises the sequences provided in the following table. In some embodiments, the composition comprises, from the 5' to the 3' end, the sequences provided in the following table.

[0088]

[0089] In some embodiments, the composition comprises the sequences of SEQ ID NO:4 and SEQ ID NO:28 from the 5' to the 3' end. In some embodiments, the composition comprises the sequences of SEQ ID NO:4, SEQ ID NO:29, and SEQ ID NO:1 from the 5' to the 3' end. In some embodiments, the composition comprises the sequences of SEQ ID NO:4, SEQ ID NO:29, CitV, SEQ ID NO:5, SEQ ID NO:1, SEQ ID NO:5, and SEQ ID NO:28 from the 5' to the 3' end. In some embodiments, the composition comprises the sequences of SEQ ID NO:4, SEQ ID NO:29, CitV, SEQ ID NO:6, SEQ ID NO:2, SEQ ID NO:5, and SEQ ID NO:28 from the 5' to the 3' end.

[0090] In some embodiments, the composition comprises the sequences of SEQ ID NO:4 and SEQ ID NO:28 from the 5' to 3' end, wherein the sequences are conjugated to each other. In some embodiments, the composition comprises the sequences of SEQ ID NO:4, SEQ ID NO:29, and SEQ ID NO:1 from the 5' to 3' end, wherein the sequences are conjugated to each other. In some embodiments, the composition comprises the sequences of SEQ ID NO:4, SEQ ID NO:29, CitV, SEQ ID NO:5, SEQ ID NO:1, SEQ ID NO:5, and SEQ ID NO:28 from the 5' to 3' end, wherein the sequences are conjugated to each other. In some embodiments, the composition comprises the sequences of SEQ ID NO:4, SEQ ID NO:29, CitV, SEQ ID NO:6, SEQ ID NO:2, SEQ ID NO:5, and SEQ ID NO:28 from the 5' to 3' end, wherein the sequences are conjugated to each other.

[0091] E. Supporting molecules

[0092] The compositions herein may also include one or more support molecules. The support molecules provided herein can be used for a range of tasks, including but not limited to protecting the DNA dendrimer and the cargo polynucleotide from nuclease degradation, enhancing transfection efficiency, aiding nuclear delivery, and compressing the size of the DNA dendrimer, the cargo polynucleotide, or both. The support molecule can be covalently or non-covalently attached to the DNA dendrimer in the same or similar manner as the targeting moiety and the cargo. However, in some embodiments, one or more support molecules are not attached to the DNA dendrimer and can be associated with the composition by other means.

[0093] Without wishing to be bound by theory, since many polynucleotide structures have negatively charged amine backbones, support molecules with sufficient positive charge can associate with the composition by charge attraction. Thus, in some embodiments, one or more support molecules associate with the composition by charge attraction. In some embodiments, one or more support molecules have a sufficiently high net positive charge to allow one or more support molecules to interact with, and optionally compact, the negatively charged DNA dendrimer. In some embodiments, one or more support molecules have a sufficiently low net positive charge to avoid aggregation or other cytotoxic side effects.

[0094] In addition, such support molecules can also be associated with both the carrier polynucleotide and the DNA dendrimer. Thus, in some embodiments, the compositions provided herein comprise a carrier polynucleotide, a support molecule, and a DNA dendrimer linked to a targeting moiety, wherein the carrier polynucleotide is not covalently linked to the DNA dendrimer. The support molecule can associate the carrier polynucleotide with the DNA dendrimer in this manner regardless of the topological structure of the carrier polynucleotide. However, when the carrier polynucleotide has a complete circular topological structure, without any cuts, sites, or regions for direct covalent attachment to the DNA dendrimer or adapter molecule, the one or more support molecules can associate the carrier polynucleotide and the DNA dendrimer together to form the composition.

[0095] The support molecules provided herein can be used alone, repeatedly, or in combination within a single molecular entity, or in combination within a complex mixture of a single molecular entity. In some embodiments, the support molecule can be added to the composition before the cargo, DNA dendrimer, and optional adapter molecule are associated. In some embodiments, the support molecule can be added to the composition after the cargo, DNA dendrimer, and optional adapter molecule are associated.

[0096] In some embodiments, the support molecule is composed of a biocompatible peptide, a polymer, or both. In some embodiments, the support molecule may comprise a cell penetrating peptide (CPP) sequence, a nuclear localization signal (NLS) sequence, or both. In some embodiments, the CPP sequence is any CPP sequence disclosed herein. In some embodiments, the NLS sequence is any NLS sequence disclosed herein.

[0097] In some embodiments, one or more support molecules have an amino acid sequence of ATPKKSTKKTPKKAKKATPKKSTKKTPKKAKK (SEQ ID NO: 12), WRRRGFGRRR (SEQ ID NO: 13), GRKKRRQRRRPQ (SEQ ID NO: 14), PKKKRKV (SEQ ID NO: 15), GLFHAIAHFIHGGWHGLIHGWYG (SEQ ID NO: 16), WEAALAEALAEALAEHLAEALAEALEALAA (SEQ ID NO: 17), HHHHHHHHHH (SEQ ID NO: 18), (KK)n (where n=2-15), or any combination thereof. In some embodiments, the support molecule has an amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVATPKKSTKKTPKKAKKATPKKSTKKTPKKAKK (SEQ ID NO: 19). In some embodiments, the support molecule has an amino acid sequence of HHHHHHHHHHATPKKSTKKTPKKAKKATPKKSTKKTPKKAKK (SEQ ID NO: 20). In some embodiments, the support molecule has an amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVGRKKRRQRRRPQWRRRGFGRRR (SEQ ID NO: 21). In some embodiments, the support molecule has an amino acid sequence of KKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 24). In some embodiments, the support molecule has an amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 25). In some embodiments, the support molecule has the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 26).

[0098] In some embodiments, polyethylene glycol (PEG) can be added to any support molecule disclosed herein. The PEG molecule can be any PEG known in the art, including various molecular weights. For example, in some embodiments, PEG is PEG400 or PEG2000. In some embodiments, the combination of PEG molecules and support molecules increases the circulation time of the support molecule, shields positive charges, enhances the stability of the composition, or any combination thereof. In some embodiments, the PEG molecule is attached to the N-terminus of the support molecule.

[0099] In some embodiments, the support molecule is added to the composition at a specific concentration. In some embodiments, the support molecule is added to the composition so that the ion balance of the entire composition is within an acceptable nitrogen / phosphate (N / P) ratio. The N / P ratio is the number of nitrogen groups in the support molecule relative to the number of phosphorus groups in any nucleic acid molecule in the composition. In some embodiments, the higher the N / P ratio, the more support molecules are added to the composition. In some embodiments, the N / P ratio is calculated using the following formula:

[0100]

[0101] In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.5 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 1 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 2 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 3 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 4 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 5 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 6 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 7 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 8 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 9 and 10. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 9. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 8. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 7. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 6. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 5. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 4. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 3. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 2. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 1. In some embodiments, the support molecule is added to the composition such that the ionic balance of the composition has an N / P ratio between 0.25 and 5.

[0102] F. Modification

[0103] Modified nucleic acids can be used throughout the compositions described herein, including DNA dendrimers, carriers, adapter molecules, and support molecules. Non-limiting examples of such chemical modifications independently include, but are not limited to, phosphate backbone modifications (e.g., phosphorothioate internucleotide linkages), nucleotide sugar modifications (e.g., 2′-O-methyl nucleotides, 2′-O-allyl nucleotides, 2′-deoxy-2′-fluoro nucleotides, 2′-deoxyribonucleotides), nucleotide base modifications (e.g., nucleotides containing “universal bases”, 5-C-methyl nucleotides), and non-nucleotide modifications (e.g., abasic nucleotides, inverted deoxy abasic residues), or combinations of these modifications. In addition, oligonucleotides having a morpholino backbone structure (U.S. Pat. No. 5,034,506) or a polyamide backbone structure (Nielsen et al., 1991, Science 254:1497) can also be used. These and other chemical modifications can maintain the biological activity of nucleic acids in vivo while significantly increasing the serum stability, potency, duration of action, and / or specificity of these compounds. Nucleic acids containing modified internucleoside linkages can also be synthesized using reagents and methods well known in the art. For example, methods for synthesizing nucleic acids containing phosphonate phosphorothioates, phosphorodithioates, phosphoramidate methoxyethyl phosphoramidate, methylal, thiomethylal, diisopropylsilyl, acetamide, carbamate, dimethylene-sulfide (—CH2—S—CH2), dimethylene-sulfoxide (—CH2—SO—CH2), dimethylene-sulfone (—CH2—SO2—CH2), 2′-O-alkyl and 2′-deoxy-2′-fluorothiophosphate internucleoside linkages are well known in the art (see Uhlmann et al., 1990, Chem. Rev. 90:543-584; Schneider et al., 1990, Tetrahedron Lett. 31:335 and references cited therein).

[0104] The examples of oligonucleotide modifications described herein are not exhaustive, and it is understood that the compositions include other modifications for enhancing the therapeutic or other properties of the oligonucleotides without significantly altering the basic sequence of the oligonucleotides. Similarly, protein cargoes may be modified as described elsewhere herein.

[0105] In addition, the linkages described herein may be non-covalent or covalent. Covalent linkages include linkages that are easily cleaved once internalized in a cell. Such linkages include pH-labile, light-labile, and radiation-labile bonds, and are well known in the art. The carrier may be linked to an oligonucleotide comprising a sequence substantially complementary to the binding arm, the binding arm being complementary to a sequence present in one of the binding arms on the surface of the DNA dendrimer, or being complementary to a portion of a single-stranded sequence of any DNA-based vector. The oligonucleotide may also comprise a nucleic acid carrier. The binding arm of a DNA dendrimer or a portion of any DNA-based vector may also be designed to comprise a sequence complementary to a sequence in a known nucleic acid molecule (e.g., genomic DNA, cDNA, RNA, plasmid, etc.) so as to directly link the nucleic acid carrier to the DNA dendrimer (via hydrogen bonding). The binding arm, branch or body of a DNA dendrimer, or a portion of any DNA-based vector may also be designed to comprise a sequence (e.g., a DNA oligonucleotide) as a carrier.

[0106] Pharmaceutical compositions and kits

[0107] In some embodiments, a pharmaceutical composition of the composition is provided. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier. For therapeutic use, the composition can be prepared as a pharmaceutical composition containing an effective amount of a carrier, composition, domain or molecule as an active ingredient in a pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle administered with an active compound. A pharmaceutically acceptable carrier is separated from the DNA dendrimer or other components provided herein. In some embodiments, the pharmaceutical composition does not have any additional pharmaceutically acceptable carrier. Such vehicles can be liquids, such as water and oils, including those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. For example, 0.4% saline and 0.3% glycine can be used. These solutions are sterile and generally do not contain insoluble particles. It can be sterilized by conventional, well-known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances required to approximate physiological conditions, such as pH adjusters and buffers, stabilizers, thickeners, lubricants and colorants, etc. The concentration of the molecules disclosed herein in such pharmaceutical preparations can vary widely, i.e., from less than about 0.5%, typically at least about 1% to as much as 15 or 20% by weight, and will be selected primarily based on the desired dose, fluid volume, viscosity, etc., according to the particular mode of administration selected. Suitable vehicles and formulations, including other human proteins, such as human serum albumin, are described, for example, in Remington: The Science and Practice of Pharmacy, 21st edition, Troy, DB ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing, pp. 691-1092, see especially pp. 958-989.

[0108] In some embodiments, any composition disclosed herein may further comprise suitable formulation agents known in the art, such as stabilizers, buffers, excipients, etc., other than support molecules or other components provided herein. For example, suitable formulation agents include, but are not limited to, purified water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, polymers (such as polyethylene glycol), propylene glycol, PEG 400, glycerol, DMA, ethanol, benzyl alcohol, citric acid / sodium citrate (pH 3), citric acid / sodium citrate (pH 5), tris(hydroxymethyl)aminomethane HCl (pH 7.0), 0.9% saline, 1.2% saline, silicone, wax, petroleum jelly, polyethylene glycol, propylene glycol, liposomes, sugars (such as mannitol and lactose), and other materials depending on the specific type of formulation used.

[0109] The mode of administration of the therapeutic use of the compositions disclosed herein can be any suitable route for delivering the agent to the host, such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary; transmucosal (oral, intranasal, intravaginal, rectal), using tablets, capsules, solutions, powders, gels, granular forms of preparations; and in syringes, implants, osmotic pumps, cartridges, micropumps; or other means known to those skilled in the art. Site administration can be achieved by, for example, intraarticular, intrabronchial, intraperitoneal, intracapsular, intracartilaginous, intracavitary, intracavitary, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intracardiac, intraosseous, intrapelvic, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravascular, intravesical, intralesional, vaginal, rectal, buccal, sublingual, intranasal or transdermal delivery.

[0110] The pharmaceutical composition can be provided as a kit comprising a container comprising a pharmaceutical composition as described herein. The pharmaceutical composition can be provided, for example, in the form of a single-dose or multi-dose injectable solution, or as a sterile powder to be reconstituted prior to injection. Such kits may also include written information about the indications and usage of the pharmaceutical composition.

[0111] method

[0112] In some embodiments, a method of delivering a target molecule to a target cell is provided. In some embodiments, the target molecule is delivered to the nucleus of the target cell. In some embodiments, the method includes contacting the target cell with any composition or pharmaceutical composition disclosed herein. Without being bound by any theory, the targeting moiety may bind to the target cell to facilitate the entry of the composition into the target cell, and wherein the carrier polynucleotide may be transported to the nucleus of the target cell. In some embodiments, the carrier polynucleotide is connected to an adapter molecule, such as any adapter molecule disclosed herein. In some embodiments, the carrier polynucleotide, the adapter molecule, or both further comprises a DTS, an NLS, or both to help transport to the nucleus of the target cell. In some embodiments, the adapter molecule comprises a CPP. In some embodiments, the carrier polynucleotide expresses the target molecule inside the nucleus of the target cell. In some embodiments, the composition of the pharmaceutical composition may express more than one target molecule. In some embodiments, one or more promoters of the carrier polynucleotide are tissue-specific promoters. In some embodiments, the targeting moiety is a tissue-specific targeting moiety. In some embodiments, the composition or pharmaceutical composition comprises two or more tissue-specific targeting moieties. In some embodiments, the targeting moiety may be any type disclosed herein.

[0113] In some embodiments, a method for treating a disease is provided. In some embodiments, the method includes contacting a target cell with any composition or pharmaceutical composition disclosed herein. In some embodiments, a targeting moiety is combined with a target cell to facilitate entry of the composition into the target cell. In some embodiments, a carrier polynucleotide can enter the nucleus of a target cell. In some embodiments, a carrier polynucleotide is connected to the DNA dendrimer. In some embodiments, a carrier polynucleotide is connected to an adapter molecule, such as any adapter molecule disclosed herein. In some embodiments, the carrier polynucleotide, the adapter molecule, or both further comprises a DTS, an NLS, or both to help transport to the nucleus of a target cell. In some embodiments, an adapter molecule comprises a CPP. In some embodiments, the carrier polynucleotide expresses the target molecule inside the nucleus of the target cell. In some embodiments, the composition of the pharmaceutical composition can express more than one target molecule. In some embodiments, one or more promoters of the carrier polynucleotide are tissue-specific promoters. In some embodiments, the targeting moiety is a tissue-specific targeting moiety. In some embodiments, a composition or pharmaceutical composition comprises two or more tissue-specific targeting moieties. In some embodiments, the targeting moiety can be any type disclosed herein.

[0114] In some embodiments, the composition is administered to a subject according to a route of administration provided herein. In some embodiments, the composition is administered parenterally, such as intravenously.

[0115] In some embodiments, the carrier of the composition is a therapeutic agent, and the method is used to alleviate a condition or disease or provide a preventive treatment for a condition or disease. The method is performed by administering any composition or medicine provided herein to an individual in need. Without being bound by any theory, by avoiding or limiting the lysosomal delivery and degradation of the carrier and successfully delivering the carrier to the nucleus of the cell, the composition and pharmaceutical composition provided herein can reduce the dosage of the therapeutic agent compared to the delivery methods of the prior art. Reducing the dosage also advantageously reduces the risk of potential side effects. In some embodiments, the therapeutic agent is a polypeptide or a small molecule drug. In other embodiments, the therapeutic agent comprises a nucleic acid. The therapeutic molecule can be any therapeutic molecule that can be encoded in a polynucleotide. Non-limiting examples of the types of therapeutic molecules that can be encoded in the expression cassettes of the present invention include, but are not limited to, peptidases, cytokines, hormones, antibodies (such as intrabodies or scFv), suicide genes (such as HSV-TK), molecules that inhibit angiogenesis, molecules that increase angiogenesis, tumor suppressors (such as p53 and p21), pro-apoptotic molecules (such as TRAIL), transcription factors, receptors, ligands, immunogenic molecules, antiproliferative molecules, agonists, antagonists, anti-inflammatory molecules, antibiotics, antidepressants, prodrugs, antihypertensives, antioxidants, etc. The therapeutic molecule comprising a nucleic acid can be a nucleic acid that regulates gene expression in vivo. Such nucleic acids include antisense molecules, siRNAs, and ribozymes.

[0116] Thus, the methods herein provide novel therapeutic approaches for a broad spectrum of diseases and conditions,

[0117] Such diseases and conditions include cancer or cancerous diseases, infectious diseases, ocular diseases, cardiovascular diseases, neurological diseases, prion diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, genetic diseases, lung diseases, kidney diseases, liver diseases, mitochondrial diseases, endocrine diseases, reproduction-related diseases and disorders, graft-versus-host disease, and any other indication that may respond to the level of a gene product expressed in a cell or individual. In some embodiments, the disease is a genetic disease or disorder including, but not limited to, spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy, Huntington disease, muscular dystrophy, machado joseph disease, choreoacanthocytosis, spastic paraplegia, dystrophia moytonica, fragile x syndrome, fragile x ataxia syndrome, spinocerebellar ataxia, frontotemporal dementia, amyotrophic lateral sclerosis, myotonic dystrophy, cystic fibrosis, and down syndrome. In some embodiments, the diseases have been shown to be treatable or potentially treatable by gene therapy, including but not limited to multiple myeloma, B-cell lymphoma, melanoma, Leber congenital amaurosis, spinal muscular atrophy, lipoprotein lipase deficiency, metachromatic leukodystrophy, mantle cell lymphoma, large B-cell lymphoma, beta thalassemia, vascular endothelial growth factor peripheral arterial disease, cerebral adrenoleukodystrophy, head and neck squamous cell carcinoma, adenosine deaminase deficiency and B-cell lymphoblastic leukemia.

[0118] The art is full of exemplary molecules and related diseases or conditions, wherein the patient may benefit from the expression of one or more molecules or the inhibition of expression. For example, the evaluation of expression changes of gene families in various human cancers has been pursued (U.S. Patent Application Publication No. 20060168670). In addition, tissue-specific expression levels have been mapped by expression profiles for thousands of genes (Alon et al., 1999, Proc. Natl. Acad. Sci. USA 96: 6745-50; Iyer et al., 1999, Science 283: 83-87; Khan et al., 1998, Cancer Res. 58: 5009-13; Lee et al., 1999, Science 285: 1390-93; Wang et al., 1999, Gene 229: 101-08; and Whitney et al., 1999, Ann. Neurol. 46: 42). Therefore, those skilled in the art can select molecules that can be used in the practice of the present invention without excessive experimentation.

[0119] In some embodiments, a method for making a cargo polynucleotide is provided, the method comprising adding at least one promoter and at least one coding sequence encoding at least one target molecule to a plasmid backbone to form a plasmid, and then optionally contacting the plasmid with one or more restriction enzymes. In some embodiments, the plasmid is contacted with one or more restriction enzymes to form various topological structures, including nicked circular nucleotides, linear nucleotides with closed 5' and 3' ends, linear nucleotides with open 5' and 3' ends, or linear nucleotides with one open end and one closed end topological structure. In some embodiments, the cargo polynucleotide is then connected to an adapter molecule, which in turn is connected to a DNA dendrimer to form the composition. In some embodiments, the plasmid is not contacted with one or more restriction enzymes to form a complete circular nucleotide topological structure. In some embodiments, the cargo polynucleotide is then contacted with a DNA dendrimer connected to a targeting moiety in the presence of a support molecule, so that the cargo polynucleotide and the DNA dendrimer are associated together to form the composition. In some embodiments, the support molecule is any support molecule described herein. In some embodiments, the support molecule compacts the size of the cargo polynucleotide, the DNA dendrimer, or both.

[0120] In some embodiments, a plasmid containing at least one coding sequence is amplified by traditional bacterial methods, such as Escherichia coli (E. coli). In some embodiments, a plasmid containing at least one coding sequence is amplified by rolling circle amplification or other non-bacterial methods. For example, amplification can be performed using enzymatic synthesis of covalently enclosed linear DNA, such as U.S. Patent No. 11,149,302 and U.S. Patent Publication No. US2019 / 0185924, both of which are incorporated herein by reference in their entirety.

[0121] Implementation

[0122] The embodiments provided herein also include but are not limited to the following:

[0123] 1. A composition comprising a DNA dendrimer linked to or associated with:

[0124] a targeting moiety; and

[0125] Adapter molecule-cargo polynucleotide complex.

[0126] 2. The composition of embodiment 1, wherein the DNA dendrimer is linked to the adapter molecule-cargo polynucleotide complex via electrostatic interaction, covalent bond, non-covalent bond or hydrogen bond with the adapter molecule.

[0127] 3. A composition as described in embodiment 1 or 2, wherein the cargo polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one target molecule, wherein the cargo polynucleotide is a nicked circular polynucleotide, a linear polynucleotide with closed 5′ and 3′ ends, a linear polynucleotide with open 5′ and 3′ ends, or a linear polynucleotide with one open end and one closed end, wherein the one open end and the one closed end can be at the 5′ and 3′ of the polynucleotide.

[0128] 4. The composition of embodiment 2, wherein the cargo polynucleotide further comprises at least one DNA targeting sequence (DTS).

[0129] 5. The composition of embodiment 4, wherein the at least one DTS is located upstream of the at least one promoter.

[0130] 6. The composition of embodiment 4, wherein the at least one DTS is located downstream of the at least one promoter.

[0131] 7. The composition of any one of embodiments 4-6, wherein the cargo polynucleotide comprises two or more DTSs.

[0132] 8. The composition of embodiment 7, wherein the two or more DTSs are positioned adjacent or approximately adjacent to each other.

[0133] 9. The composition of embodiment 7, wherein the two or more DTSs are not positioned adjacent or approximately adjacent to each other.

[0134] 10. The composition of any one of embodiments 1-5, wherein the cargo polynucleotide further comprises at least one nuclear localization signal sequence (NLS).

[0135] 11. The composition of embodiment 10, wherein the at least one NLS is located upstream of the at least one promoter.

[0136] 12. The composition of embodiment 10, wherein the at least one NLS is located downstream of the at least one promoter.

[0137] 13. The composition of any one of embodiments 6-8, wherein the cargo polynucleotide comprises at least one DTS and at least one NLS.

[0138] 14. The composition of any one of embodiments 1-9, wherein the adapter molecule comprises a DNA dendrimer binding sequence (DBS) and a cargo binding region (CBR).

[0139] 15. The composition of embodiment 14, wherein the adaptor is linked to the DNA dendrimer via the DBS.

[0140] 16. The composition of embodiment 14 or 15, wherein the DBS comprises a nucleic acid sequence complementary to a nucleic acid sequence on the DNA dendrimer.

[0141] 17. A composition as described in any of embodiments 14-16, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO:3), CCTCAGCTGTACTCTAGTTGTTACCTCTAATGCTGGACCTCA GC (SEQ ID NO:22), or CCTCAGCACCCTACAGAGTAACCTA GATTGATCAAACACCTCAGC (SEQ ID NO:23).

[0142] 18. The composition of any one of embodiments 14-17, wherein the DBS further comprises a polythymine sequence at the 5' or 3' end of the DBS.

[0143] 19. The composition of embodiment 18, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTTT (SEQ ID NO: 4).

[0144] 20. The composition of any one of embodiments 14-19, wherein the cargo binding region (CBR) is capable of being linked to the cargo polynucleotide via DNA ligation, i.e., linked to the polynucleotide via a covalent bond such as a phosphodiester bond.

[0145] 21. A composition as described in any of embodiments 14-19, wherein the CBR is capable of being linked to the cargo polynucleotide by chemical coupling, i.e., linked to the polynucleotide by a covalent bond such as a disulfide bond.

[0146] 22. The composition of any one of embodiments 14-21, wherein the cargo binding region comprises at least one cysteine.

[0147] 23. The composition of any one of embodiments 14-22, wherein the adapter molecule further comprises a tag, such as a tag that can be used as an affinity tag to isolate / purify the composition complex.

[0148] 24. The composition of embodiment 23, wherein the tag is located between the DBS and the CBR.

[0149] 25. The composition of embodiment 24, wherein the tag is a polyhistidine tag.

[0150] 26. The composition of any one of embodiments 14-25, wherein the adapter molecule further comprises at least one nuclear localization signal sequence (NLS).

[0151] 27. The composition of embodiment 26, wherein the at least one NLS is located between or overlaps with the DBS and the cargo binding region.

[0152] 28. The composition of embodiment 26 or 27, wherein the at least one NLS comprises one or more NLS sequences disclosed herein.

[0153] 29. The composition of any one of embodiments 26-28, wherein the at least one NLS comprises the amino acid sequence of YPDEVKRKKKP (SEQ ID NO: 1).

[0154] 30. The composition of any one of embodiments 26-28, wherein the at least one NLS comprises the amino acid sequence of SLLESPFDKPDEVKRKKKPPTSHQSDATAEDDSSS SKKK (SEQ ID NO: 2).

[0155] 31. The composition of any one of embodiments 26-30, wherein the at least one NLS further comprises at least one spacer located before or after the at least one NLS.

[0156] 32. A composition as described in embodiment 31, wherein the at least one NLS comprises two spacers located before or after the at least one NLS, such as one spacer located before the NLS and one spacer located after the NLS, or two spacers located before or after the NLS.

[0157] 33. A composition as described in embodiment 31 or 32, wherein the one or more spacers comprise polyethylene glycol (PEG), propylene glycol alginate (PGA), PEG-polylactic acid (PLA), polylactic-co-glycolic acid (PGLA), or any combination thereof.

[0158] 34. A composition as described in embodiment 31 or 32, wherein the one or more spacers comprise a poly-glycine sequence, optionally with alanine and / or serine residues.

[0159] 35. The composition of embodiment 34, wherein the one or more spacers have an amino acid sequence of GGGG (SEQ ID NO: 5).

[0160] 36. The composition of any one of embodiments 14-35, wherein the adapter molecule further comprises at least one DNA targeting sequence (DTS).

[0161] 37. The composition of embodiment 36, wherein the at least one DTS is located between or overlaps the DBS and the CBR.

[0162] 38. The composition of any one of embodiments 14-37, wherein the adapter molecule further comprises a cell penetrating peptide sequence (CPP).

[0163] 39. The composition of embodiment 38, wherein the CPP is located between or overlaps with the DBS and the CBR.

[0164] 40. The composition of embodiment 38 or 39, wherein the CPP comprises a CPP disclosed herein.

[0165] 41. The composition of any one of embodiments 38-40, wherein the CPP comprises an amino acid sequence of QPRRRPRRKKRG (SEQ ID NO: 6).

[0166] 42. The composition of any one of embodiments 14-41, wherein the adapter molecule further comprises at least one cleavage site.

[0167] 43. The composition of embodiment 42, wherein the at least one cleavage site is located between or overlaps with the DBS and the CBR.

[0168] 44. The composition of embodiment 42 or 43, wherein the cleavage site is located near the DBS.

[0169] 45. The composition of any one of embodiments 42-44, wherein the cleavage site is a val-cit linker.

[0170] 46. ​​The composition of any one of embodiments 14-45, wherein the adapter molecule further comprises at least one flexible linker.

[0171] 47. The composition of embodiment 46, wherein the at least one flexible linker is located between the DNS and the CBR.

[0172] 48. A composition as described in embodiment 46 or 47, wherein the at least one flexible linker is selected from polyethylene glycol (PEG), propylene glycol alginate (PGA), PEG-polylactic acid (PLA), polylactic-co-glycolic acid (PGLA), (GG)n, (GGGGS)n or (GGGGA)n, wherein each n is independently 1-5.

[0173] 49. The composition of any one of embodiments 1-47, wherein the composition further comprises a support molecule.

[0174] 50. The composition of embodiment 49, wherein the support molecule is attached to the DNA dendrimer.

[0175] 51. The composition of embodiment 49, wherein the support molecule is not attached to the DNA dendrimer.

[0176] 52. The composition of any one of embodiments 49-51, wherein the support molecule compacts the size of the cargo polynucleotide, the DNA dendrimer, or both.

[0177] 53. A composition as described in any of embodiments 49-52, wherein the support molecule is capable of facilitating nuclear delivery.

[0178] 54. The composition of any one of embodiments 49-53, wherein the support molecule is capable of protecting the cargo polynucleotide, the DNA dendrimer, or both from nuclease degradation.

[0179] 55. The composition of any one of embodiments 49-54, wherein the support molecule is capable of enhancing the transfection efficiency of the composition.

[0180] 56. The composition of any one of embodiments 49-55, wherein the support molecule comprises an amino acid sequence of ATPKKSTKKTPKKAKKATPKKSTKKTPKKKAKK (SEQ ID NO: 12), WRRRGFGRRR (SEQ ID NO: 13), GRKKRRQR RRPQ (SEQ ID NO: 14), PKKKRKV (SEQ ID NO: 15), GLF HAIAHFIHGGWHGLIHGWYG (SEQ ID NO: 16), WEAALAEA LAEALAEHLAEALAEALEALAA (SEQ ID NO: 17), HHHHHH HHHH (SEQ ID NO: 18), (KK)q, wherein q is 2-15.

[0181] 57. The composition of any one of embodiments 49-56, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVAT PKKSTKKTPKKAKKATPKKSTKKTPKKAKK (SEQ ID NO: 19).

[0182] 58. The composition of any one of embodiments 49-56, wherein the support molecule comprises the amino acid sequence of HHHHHHHHHHATPKKSTKKTPKKAKKATPKKSTKK TPKKAKK (SEQ ID NO: 20).

[0183] 59. The composition of any one of embodiments 49-56, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVG RKKRRQRRRPQWRRRGFGRRR (SEQ ID NO: 21).

[0184] 60. The composition of any one of embodiments 49-56, wherein the support molecule comprises an amino acid sequence of KKKKKKKKKKKKKKKKKKK (SEQ ID NO: 24).

[0185] 61. The composition of any one of embodiments 49-56, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 25).

[0186] 62. The composition of any one of embodiments 49-56, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 26).

[0187] 63. A composition as described in any of embodiments 1-62, wherein the targeting moiety is selected from an antibody, a naturally occurring ligand of a receptor or a functional derivative thereof, a vitamin, a hormone, a small molecule mimetic of a naturally occurring ligand, a peptide, a polypeptide, a peptide mimetic, a carbohydrate, a lipid, an aptamer, a nucleic acid, a toxin, a component of a microorganism, any other molecule, provided that it specifically binds to a cell surface molecule and induces endocytosis of the bound portion, or any combination thereof.

[0188] 64. A composition comprising a cargo polynucleotide, a support molecule, and a DNA dendrimer linked to a targeting moiety.

[0189] 65. The composition of embodiment 64, wherein the targeting moiety is selected from antibodies, naturally occurring ligands of receptors or functional derivatives thereof, vitamins, hormones, small molecule mimetics of naturally occurring ligands, peptides, polypeptides, peptide mimetics, carbohydrates, lipids, aptamers, nucleic acids, toxins, components of microorganisms, any other molecule, provided that it specifically binds to a cell surface molecule and induces endocytosis of the bound portion, or any combination thereof.

[0190] 66. The composition of embodiment 64 or 65, wherein:

[0191] The cargo polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one target molecule, and optionally a DNA binding sequence (DBS),

[0192] wherein the cargo polynucleotide is a complete circular polynucleotide (e.g., a plasmid), a nicked circular polynucleotide, a linear polynucleotide with closed 5′ and 3′ ends, a linear polynucleotide with open 5′ and 3′ ends, or a linear polynucleotide with one open end and one closed end,

[0193] Wherein the one open end and the one closed end can be at 5' and 3' of the cargo polynucleotide.

[0194] 67. The composition of embodiment 66, wherein the cargo polynucleotide is a closed circular polynucleotide.

[0195] 68. The composition of embodiment 66, wherein the cargo polynucleotide is a nicked circular polynucleotide.

[0196] 69. The composition of any one of embodiments 64-68, wherein the cargo polynucleotide is not covalently linked to the DNA dendrimer.

[0197] 70. The composition of any one of embodiments 64-69, wherein the cargo polynucleotide further comprises at least one DNA targeting sequence (DTS).

[0198] 71. The composition of embodiment 70, wherein the DTS is located within the cargo polynucleotide.

[0199] 72. The composition of embodiment 70, wherein the DTS is linked to the cargo polynucleotide.

[0200] 73. The composition of embodiment 72, wherein the cargo polynucleotide is a nicked circular polynucleotide and the DTS is linked to the cargo polynucleotide at the single-stranded DNA break (ie, the location of the nick).

[0201] 74. The composition of any one of embodiments 64-73, wherein the cargo polynucleotide further comprises at least one nuclear localization signal sequence (NLS).

[0202] 75. The composition of any one of embodiments 64-74, wherein the cargo polynucleotide comprises at least one DTS and at least one NLS.

[0203] 76. A composition as described in any of embodiments 66-75, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO: 3), CCTCAGCTGTACTCTAGTTGTTACCTCTAATGCTGGACCTCA GC (SEQ ID NO: 22), or CCTCAGCACCCTACAGAGTAACCTA GATTGATCAAACACCTCAGC (SEQ ID NO: 23).

[0204] 77. The composition of embodiment 76, wherein the DBS further comprises a polythymine sequence at the 5' or 3' end of the DBS.

[0205] 78. The composition of embodiment 77, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTTT (SEQ ID NO: 4).

[0206] 79. The composition of any one of embodiments 64-78, wherein the support molecule is attached to the DNA dendrimer.

[0207] 80. The composition of any one of embodiments 64-79, wherein the support molecule is not attached to the DNA dendrimer.

[0208] 81. The composition of any one of embodiments 64-80, wherein the support molecule compacts the size of the cargo polynucleotide, the DNA dendrimer, or both.

[0209] 82. The composition of any one of embodiments 64-81, wherein the support molecule is capable of facilitating nuclear delivery.

[0210] 83. The composition of any one of embodiments 64-82, wherein the support molecule is capable of protecting the cargo polynucleotide, the DNA dendrimer, or both from nuclease degradation.

[0211] 84. The composition of any one of embodiments 64-83, wherein the support molecule is capable of enhancing the transfection efficiency of the composition.

[0212] 85. The composition of any one of embodiments 64-84, wherein the presence of the support molecule facilitates the association of the cargo polynucleotide and the DNA dendrimer with each other.

[0213] 86. The composition of any one of embodiments 64-85, wherein the support molecule has a positive charge.

[0214] 87. The composition of any one of embodiments 64-86, wherein the support molecule comprises an amino acid sequence of ATPKKSTKKTPKKAKKATPKKSTKKTPKKKAKK (SEQ ID NO: 12), WRRRGFGRRR (SEQ ID NO: 13), GRKKRRQR RRPQ (SEQ ID NO: 14), PKKKRKV (SEQ ID NO: 15), GLF HAIAHFIHGGWHGLIHGWYG (SEQ ID NO: 16), WEAALAEA LAEALAEHLAEALAEALEALAA (SEQ ID NO: 17), HHHHHH HHHH (SEQ ID NO: 18), (KK)q, or any combination thereof, wherein q is 2-15.

[0215] 88. The composition of any one of embodiments 64-87, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVAT PKKSTKKTPKKAKKATPKKSTKKTPKKAKK (SEQ ID NO: 19).

[0216] 89. The composition of any one of embodiments 64-87, wherein the support molecule comprises the amino acid sequence of HHHHHHHHHHATPKKSTKKTPKKAKKATPKKSTKK TPKKAKK (SEQ ID NO: 20).

[0217] 90. The composition of any one of embodiments 64-87, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVG RKKRRQRRRPQWRRRGFGRRR (SEQ ID NO: 21).

[0218] 91. The composition of any one of embodiments 64-87, wherein the support molecule comprises an amino acid sequence of KKKKKKKKKKKKKKKKKKK (SEQ ID NO: 24).

[0219] 92. The composition of any one of embodiments 64-87, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 25).

[0220] 93. The composition of any one of embodiments 64-87, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 26).

[0221] 94. The composition of any one of embodiments 64-93, wherein the support molecule further comprises a polyethylene glycol (PEG) molecule attached to the support molecule.

[0222] 95. The composition of embodiment 94, wherein the polyethylene molecule is PEG2000.

[0223] 96. A composition as described in embodiment 94 or 95, wherein the PEG molecule is attached to the N-terminus of the support molecule.

[0224] 97. The composition of any one of embodiments 1-97, wherein the coding sequence of the cargo polynucleotide encodes an antibody, an enzyme, a protein, a miRNA, a siRNA, an antisense RNA, etc.

[0225] 98. The composition of any one of embodiments 1-97, wherein the nitrogen / phosphate (N / P) ratio of the composition is between 0.5 and 10.

[0226] 99. The composition of embodiment 98, wherein the N / P ratio of the composition is between 2 and 5.

[0227] 100. A pharmaceutical composition comprising the composition of any one of embodiments 1-99 and a pharmaceutically acceptable carrier.

[0228] 101. A method for delivering a target molecule to the nucleus of a target cell, the method comprising contacting the target cell with a composition as described in any of embodiments 1-99 or a pharmaceutical composition as described in embodiment 100, wherein the targeting moiety binds to the target cell.

[0229] 102. The method of embodiment 101, wherein the cargo polynucleotide expresses the target molecule in the nucleus of the target cell.

[0230] 103. A method as described in embodiment 101 or 102, wherein the cargo polynucleotide expresses two or more target molecules in the nucleus of the target cell.

[0231] 104. The method of any one of embodiments 101-103, wherein the cargo polynucleotide comprises a tissue-specific promoter.

[0232] 105. The method of any one of embodiments 101-104, wherein the targeting moiety is a tissue-specific targeting moiety.

[0233] 106. The method of any one of embodiments 101-105, wherein the composition or pharmaceutical composition comprises two or more targeting moieties.

[0234] 107. A method of treating a disease, the method comprising administering the composition of any one of embodiments 1-99 or the pharmaceutical composition of embodiment 100 to a subject to treat the disease, wherein the targeting moiety binds to the target cell.

[0235] 108. A method as described in embodiment 107, wherein the cargo polynucleotide expresses the target molecule in the nucleus of the target cell.

[0236] 109. The method of embodiment 107 or 108, wherein the cargo polynucleotide expresses two or more target molecules in the nucleus of the target cell.

[0237] 110. The method of any one of embodiments 107-109, wherein the cargo polynucleotide comprises a tissue-specific promoter.

[0238] 111. The method of any one of embodiments 107-110, wherein the targeting moiety is a tissue-specific targeting moiety.

[0239] 112. The method of any one of embodiments 107-111, wherein the composition or pharmaceutical composition comprises two or more targeting moieties.

[0240] 113. A plasmid comprising a plasmid backbone comprising at least two enzyme restriction recognition sites, at least one promoter, at least one coding sequence encoding at least one target molecule and optionally a DNA dendrimer binding sequence (DBS), wherein the plasmid is capable of forming a cargo polynucleotide having various structures depending on whether the plasmid has one or more of a 5′ end and a 3′ end or has no such ends.

[0241] 114. The plasmid of embodiment 113, wherein the plasmid is a complete circular polynucleotide, a nicked circular polynucleotide, a linear polynucleotide with closed 5' and 3' ends, a linear polynucleotide with open 5' and 3' ends, and a linear polynucleotide with one open end and one closed end.

[0242] 115. The plasmid of embodiment 113, wherein the nicked circular nucleotides, the linear nucleotides with closed 5' and 3' ends, the linear nucleotides with open 5' and 3' ends, and the linear nucleotides with one open end and one closed end are formed by cutting the plasmid with one or more restriction enzymes.

[0243] 116. The plasmid of any one of embodiments 113-115, wherein the plasmid further comprises at least one DNA targeting sequence (DTS).

[0244] 117. A plasmid as described in embodiment 116, wherein the at least one DTS is located in the plasmid backbone, that is, between or overlapping with the at least two enzyme restriction recognition sites.

[0245] 118. The plasmid of embodiment 116 or 117, wherein the at least one DTS is located upstream of the at least one promoter.

[0246] 119. The plasmid of embodiment 116 or 117, wherein the at least one DTS is located downstream of the at least one promoter.

[0247] 120. The plasmid of any one of embodiments 113-119, wherein the cargo polynucleotide further comprises at least one nuclear localization signal sequence (NLS).

[0248] 121. The plasmid of embodiment 120, wherein the at least one NLS is located upstream of the at least one promoter.

[0249] 122. The plasmid of embodiment 120, wherein the at least one NLS is located downstream of the at least one promoter.

[0250] 123. The plasmid of any one of embodiments 116-122, wherein the cargo polynucleotide comprises at least one DTS and at least one NLS.

[0251] 124. The composition of any one of embodiments 116-123, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO: 3), CCTCAGCTTGTACTCTAGTTGTTACCTCTAATGCTGGACCTCAGC (SEQ ID NO: 22), or CCTCAGCACCCTACAGAGTAACCTAGATTGATCAAACACCTCAGC (SEQ ID NO: 23).

[0252] 125. The composition of embodiment 124, wherein the DBS further comprises a polythymine sequence at the 5' or 3' end of the DBS.

[0253] 126. The composition of embodiment 125, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTT (SEQ ID NO: 4).

[0254] 127. The plasmid of any one of embodiments 116-126, wherein the at least one promoter is a tissue-specific promoter.

[0255] 128. The plasmid of any one of embodiments 116-126, wherein the plasmid comprises a polynucleotide sequence encoding two or more target molecules.

[0256] 129. A method of making a composition according to any one of embodiments 1-63, the method comprising:

[0257] contacting a plasmid as described in any of embodiments 113-129 with one or more restriction enzymes that cut at the restriction enzyme recognition site to form a nicked circular polynucleotide, a linear polynucleotide with closed 5' and 3' ends, a linear polynucleotide with open 5' and 3' ends, or a linear polynucleotide with one open end and one closed end,

[0258] ligating the cargo polynucleotide to the adapter molecule to form an adapter molecule-cargo polynucleotide complex, and

[0259] The adapter molecule-cargo polynucleotide complex and the targeting moiety are linked to a DNA dendrimer to form the composition.

[0260] 130. A method of making a composition according to any one of embodiments 64-99, the method comprising:

[0261] contacting a plasmid according to any one of embodiments 113 to 129 comprising a DNA dendrimer binding sequence (DBS) with one or more restriction enzymes that cleave at the restriction enzyme recognition site to form a nicked circular polynucleotide, a linear polynucleotide with closed 5′ and 3′ ends, a linear polynucleotide with open 5′ and 3′ ends, or a linear polynucleotide with one open end and one closed end, and

[0262] The cargo polynucleotide and targeting moiety are linked to a DNA dendrimer to form the composition.

[0263] 131. A method of making a composition as described in any one of embodiments 64-99, the method comprising

[0264] The circular uncut plasmid of any one of embodiments 113-129 having a DNA dendrimer attached to a targeting moiety is contacted with a support molecule capable of compacting the size of the cargo polynucleotide and the DNA dendrimer such that the cargo polynucleotide and the DNA dendrimer associate together to form the composition.

[0265] 132. A kit comprising the composition of embodiments 1-99, the pharmaceutical composition of embodiment 100, the plasmid of any one of embodiments 113-129, or a combination thereof.

[0266] Example

[0267] The following examples are provided for illustrative purposes only, and the claims should in no way be construed as being limited to these examples, but rather should be construed as covering any and all variations that become apparent as a result of the teachings provided herein. Those skilled in the art will readily recognize a variety of non-critical parameters that can be changed or modified to produce substantially similar results.

[0268] Example 1: Characterization of various topological structures of polynucleotide cargo

[0269] To determine how the topology of various polynucleotide carriers affects expression efficiency, gene cassettes containing luciferase and eGFP driven by a CMV promoter were inserted into a plasmid backbone containing multiple restriction enzyme recognition sites, including SalI, BbcCI, and Tel. To generate various topologies, the resulting plasmids were cut with the following restriction enzymes listed in Table 1. The various topologies are depicted in Figure 1 Shown in.

[0270] Table 1: Plasmid topology

[0271]

[0272] Once established, each polynucleotide carrier was transfected into CHO-K1 cells using equimolar amounts of each topo variant. GFP expression was measured over time using cell imaging and quantitative fluorescence measurements. The percentage of GFP-positive cells and total fluorescence intensity were compared. Results are shown in Table 1. Figure 2 and Figure 3 The unmodified complete circular (ie, plasmid) and linear topologies with 2 closed ends generally had the best overall fluorescence activity, however all topologies had active fluorescence, which can be useful if changes in overall activity are desired for a particular therapeutic agent.

[0273] Example 2: Nuclear localization in non-dividing cells

[0274] In many cases, it is important to deliver the carrier polynucleotide to the nucleus of the target cell to express the encoded target molecule. When the cell divides, the nuclear membrane naturally decomposes, allowing direct access from the cytoplasm. However, in the absence of mitosis, the nuclear membrane remains intact and the plasmid is essentially impermeable. A potential strategy is to include at least one copy of a DNA targeting sequence (DTS), a nuclear localization sequence (NLS), or both, an adapter molecule that can be associated with the carrier polynucleotide, or both, in the carrier polynucleotide. In healthy cytoplasm, transcription factors, including NLS, can bind to DTS and recruit carriers for nuclear transport. Similarly, NLS can directly recruit essential import proteins (importin) to read carriers for nuclear transport. In order to test this general strategy, DTS is included in a polynucleotide plasmid expressing eGFP and compared with a plasmid expressing eGFP without DTS in three different cell lines: fast-growing CHO-K1, medium-growing A427, and relatively slowly dividing C2C12 differentiated myoblasts.

[0275] Generally, both the DTS-free plasmid (P1A) and the DTS plasmid (P1B) can be grown in CHO-K1 ( Figure 4 ) and A427 cell lines ( Figure 5 ) expressed GFP. This was expected, as both cell lines undergo sufficient mitosis to allow easy entry into the nucleus. However, in the C2C12 cell line, where there is no to slow growth rate limiting entry into an otherwise intact nucleus, the plasmid vector containing the DTS showed a significant decrease in relative mean fluorescence ( Figure 6 ), relative integrated fluorescence ( Figure 7 ) and relative peak fluorescence ( Figure 8 ) had significantly better expression than the control plasmid. Figure 4-8 Approximately 5,000 cells / well were plated and imaging and quantification of fluorescence was measured 24 hours after initial transfection. Significance was determined using one-way ANOVA and Tukey's multiple comparison test between groups; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

[0276] Example 3: Additional Characterization of Various Topologies of Polynucleotide Carriers

[0277] Additional polynucleotide carrier plasmids were prepared and tested.

[0278] Reporter gene constructs

[0279] All reporter constructs contained bacterial selection sequences (antibiotic resistance, replication origin (ORI)), SV40-DTS, codon-optimized firefly luciferase (Luc2_CO), codon-optimized enhanced green fluorescent protein (eGFP_CO), 2A self-cleaving peptide (P2A), and bovine growth hormone polyadenylation (bgh-PolyA) signal. In addition, the TelN telomerase sequence was used in combination with one of two DBS sequences (SEQ ID NO: 22 or SEQ ID NO: 23) that allow plasmid attachment to DNA dendrimer nanoparticles via complementary hybridization. Two nickase sites flanking the DBS enzyme were used to expose single-stranded DNA (ssDNA) sequences to the selected attachment arms of the synthetic scaffold.

[0280] Three reporter constructs were prepared. Reporter constructs 1 and 2 share a cytomegalovirus (CMV) enhancer and promoter, which are known to be used for robust and ubiquitous expression in mammalian cell lines. Both reporter constructs also share a Kozak sequence for initiating eukaryotic translation. Reporter construct 1 has a DBS sequence of SEQ ID NO:22, while reporter construct 2 has a DBS sequence of SEQ ID NO:23. Reporter construct 3 has a DBS sequence of SEQ ID NO:22, but has a different promoter: muscle-specific promoter mCK8e. All three reporter constructs have various cleavage sites for restriction enzymes, and double nickase sites are placed for plasmid manipulation. The region containing the selected enzyme cleavage site and attachment sequence is called the "CB backbone element" region. Another feature of this region is the TelN telomerase recognition site. This sequence is a palindromic sequence and forms two covalently closed ends (denoted as "TelR" and "TelL") at the cleavage site when recognized by the enzyme.

[0281] In addition, a target molecule construct was prepared in which the DNA insert encoding the construct was greater than 10K base pairs. The construct had many of the same sequences found in the reporter gene construct: bacterial selection portion, SV40-DTS, mCK8e promoter, Kozak sequence, and TelN telomerase site. An additional promoter, i.e., T7 promoter, was integrated before the coding sequence to enhance bacterial expression. Similar restriction enzyme and double nickase sites were present near the DBS sequence (SEQ ID NO: 22).

[0282] method

[0283] Restriction enzymes used only with reporter gene constructs Indicates that only restriction enzymes used with the 10K insert construct were used Nickases denoted as "Nt" were used only with constructs having a DBS site of SEQ ID NO: 22. Nickases denoted as "Nb" were used only with constructs having a DBS site of SEQ ID NO: 23. Any enzyme or nickase without a symbol is universal and can be used with any of the constructs listed.

[0284] 1. Open ring with cutout (OpC)

[0285] Constructs with SEQ ID NO: 22 DBS sites were incubated with Nt.BbvCI at a ratio of 1 μg plasmid: 1 unit (U) enzyme (10,000 U / mL, New England Biolabs, R0632L, lot 10141032). Those constructs with SEQ ID NO: 23 DBS sites were incubated with Nb.BbvCI at a ratio of 1 μg plasmid: 1 U enzyme (10,000 U / mL, New England Biolabs, R0631L, lot 10150965). The reactions were then incubated at 50° C. at 300 rpm for 1 hour.

[0286] A 20 μmol excess of the appropriate capture sequence for the DBS site was then added to the plasmid. The reaction was then heated to 90°C for 2 minutes to allow the nicked strand to dissociate from the plasmid. Afterwards, the reaction was slowly cooled to room temperature over 3.5 hours, allowing the capture sequence to bind to the nicked sequence and open the attachment site.

[0287] The nicked plasmid is then separated from the captured nicked sequence using ion exchange chromatography (IEX). The fractions containing the peak of interest are then combined and the OpC plasmid is extracted using ethanol (EtOH) precipitation. The pellet is then dried and re-dissolved in the buffer of choice.

[0288] 2. Linear Notch (LN)

[0289] The construct was incubated with TelN telomerase at a ratio of 1 μg plasmid: 1 U enzyme (20,000 U / mL, New England Biolabs, M0651B-HC2, lot 10151691). The reaction was incubated at 30°C and 300 rpm for 4 hours. The buffer was exchanged into nuclease-free water to remove Triton-X from the initial buffer.

[0290] TelN linearized constructs with SEQ ID NO: 22 DBS site were incubated with Nt.BbvCI at a ratio of 1 μg plasmid: 1 unit (U) enzyme (10,000 U / mL, New England Biolabs, R0632L, lot 10141032). Those constructs with SEQ ID NO: 23 DBS site were incubated with Nb.BbvCI at a ratio of 1 μg plasmid: 1 U enzyme (10,000 U / mL, New England Biolabs, R0631L, lot 10150965). The reaction was then incubated at 50°C at 300 rpm for 1 hour.

[0291] A 20 μmol excess of the appropriate capture sequence for the DBS site was then added to the plasmid. The reaction was then heated to 90°C for 2 minutes to allow the nicked strand to dissociate from the plasmid. Afterwards, the reaction was slowly cooled to room temperature over 3.5 hours, allowing the capture sequence to bind to the nicked sequence and open the attachment site.

[0292] IEX is then used to separate the nicked plasmid from the captured nicked sequence. The fractions containing the peak of interest are then pooled and the LN plasmid is extracted using EtOH precipitation. The pellet is then dried and reconstituted in the buffer of choice.

[0293] 3.1-Open, 1-Closed (1co)

[0294] The construct was incubated with TelN telomerase at a ratio of 1 μg plasmid: 1 U enzyme (20,000 U / mL, New England Biolabs, M0651B-HC2, lot 10151691). The reaction was incubated at 30°C and 300 rpm for 4 hours. The buffer was exchanged into nuclease-free water to remove Triton X from the initial buffer.

[0295] Will (20,000U / mL, New England Biolabs, R3589L, Lot No. 10150327) or (100,000 U / mL, New England Biolabs, R3505M, lot number 10157687) was incubated with TelN linearized construct at a ratio of 1 μg plasmid: 1 U enzyme. The reaction was incubated at 37°C at 300 rpm for 1 hour. EtOH precipitation was used to precipitate the 1-open-ended linearized plasmid before the nickase reaction.

[0296] Constructs with SEQ ID NO: 22 DBS sites were incubated with Nt.BbvCI at a ratio of 1 μg plasmid: 1 unit (U) enzyme (10,000 U / mL, New England Biolabs, R0632L, lot 10141032). Those constructs with SEQ ID NO: 23 DBS sites were incubated with Nb.BbvCI at a ratio of 1 μg plasmid: 1 U enzyme (10,000 U / mL, New England Biolabs, R0631L, lot 10150965). The reactions were then incubated at 50° C. at 300 rpm for 1 hour.

[0297] A 20 μmol excess of the appropriate capture sequence for the DBS site was then added to the plasmid. The reaction was then heated to 90°C for 2 minutes to allow the nicked strand to dissociate from the plasmid. Afterwards, the reaction was slowly cooled to room temperature over 3.5 hours, allowing the capture sequence to bind to the nicked sequence and open the attachment site.

[0298] IEX is then used to separate the nicked plasmid from the captured nicked sequence. The fractions containing the peak of interest are then pooled and the 1co plasmid is extracted using EtOH precipitation. The pellet is then dried and reconstituted in the buffer of choice.

[0299] 4.2-Open end (2oe)

[0300] Will (20,000U / mL, New England Biolabs, R3589L, Lot No. 10150327) or (100,000 U / mL, New England Biolabs, R3505M, lot 10157687) was incubated with the construct at a ratio of 1 μg plasmid: 1 U enzyme. The reaction was incubated at 37°C at 300 rpm for 1 hour. The 2oe linearized plasmid was precipitated using EtOH precipitation and then re-dissolved in the buffer of its choice.

[0301] Constructs with SEQ ID NO: 22 DBS sites were incubated with Nt.BbvCI at a ratio of 1 μg plasmid: 1 unit (U) enzyme (10,000 U / mL, New England Biolabs, R0632L, lot 10141032). Those constructs with SEQ ID NO: 23 DBS sites were incubated with Nb.BbvCI at a ratio of 1 μg plasmid: 1 U enzyme (10,000 U / mL, New England Biolabs, R0631L, lot 10150965). The reactions were then incubated at 50° C. at 300 rpm for 1 hour.

[0302] A 20 μmol excess of the appropriate capture sequence for the DBS site was then added to the plasmid. The reaction was then heated to 90°C for 2 minutes to allow the nicked strand to dissociate from the plasmid. Afterwards, the reaction was slowly cooled to room temperature over 3.5 hours, allowing the capture sequence to bind to the nicked sequence and open the attachment site.

[0303] IEX is then used to separate the nicked plasmid from the captured nicked sequence. The fractions containing the peak of interest are then pooled and the 1co plasmid is extracted using EtOH precipitation. The pellet is then dried and reconstituted in the buffer of choice.

[0304] Confirm the result

[0305] Unless otherwise stated, reporter construct 1 was used for all experiments.

[0306] 1. Confirmation of OpC plasmid.

[0307] Use restriction fragment length polymorphism (RFLP) analysis, evaluate the effect of double nickase on 15% TBE-urea denaturing polyacrylamide gel.The plasmid before modification does not show gel band, and the plasmid after nickase shows 38bp band, which is related to the expected band size of cutting.For RFLP, use TelN to open plasmid, and then further cut from the nicking site with other restriction enzyme.Produce 2 smaller fragments (47 and 58bp) from the chain of top band nicking like this, and produce a longer fragment (209bp) from the bottom chain (bottomstrand).In addition, because this analysis is run before IEX purification, there is 38bp band from nickase.These bands are related to the expected size from nicking.

[0308] In order to observe whether the modified plasmid is still functional, HepG2 cells were transfected with the reporter construct 1 of the OpC topology using Lipofectamine 2000 (Catalog No. 11668019, ThermoFisher Scientific, Waltham, MA). Cells were seeded with ~2.5x104 cells / well the day before treatment. After 48 hours, due to eGFP expression, cells were subjected to fluorescence imaging (excitation / emission 488 / 509nm). The sum of the integrated fluorescence intensity was used to quantify the fluorescence signal, which allows the representation of a single pixel without deviation. The results show that the reporter construct 1 has a high fluorescence signal distribution.

[0309] 2. Confirmation of linear nicked (LN) plasmid.

[0310] For the RFLP of the LN plasmid, since the plasmid had already been treated with TelN, only an additional restriction enzyme upstream of the nickase site was required. As expected, the 38 bp band was present as well as the 47, 58 and 209 bp bands due to the nickase.

[0311] 3. Confirmation of 1-open and 1-closed (1co) plasmids

[0312] RFLP performed on the 1co plasmid showed that the 132 bp band from the blocked ends removed and the 30 bp band from the check cleavage were present as expected before the addition of nickase. The 132, 48, 46 and 38 bp bands were added after nickase RFLP, with smaller fragments of the nicked strands generated by the removal of the blocked ends and excised DNA fragments, all as expected.

[0313] Example 4: Characterization of Support Molecules for Complexation and Protection of Polynucleotide Cargo

[0314] Nucleases are enzymes that cleave the phosphodiester bonds between the nucleotides of nucleic acids. They are often present in DNA repair mechanisms, such as replication proofreading, Okazaki fragment processing, mismatch repair, base excision repair, nucleotide excision repair, and double-strand break repair. For nucleic acid-based gene delivery methods, nucleases can be large inhibitors that are active by destroying the payload before it can be transcribed (in the case of DNA) or translated (in the case of ribonucleic acid RNA).

[0315] Another factor to consider for in vivo delivery is the size of the nanocarriers with and without payload. Pore size varies by cell type and will only allow uptake of material of the same size. The size of DNA dendrimer nanocarriers is approximately 60 nm. Depending on the topology of the payload, this can significantly increase the particle size. Previously measured linearized pDNA was approximately 750 nm in length after hybridization with DNA dendrimers. To enable delivery to cells with smaller pore sizes, the particles must be reduced or compacted.

[0316] In addition to size, particle size and protection can also increase the durability of scaffolds and cargoes. Support molecules can both compact the nanoparticles and shield them from degrading enzymes. These support molecules can be peptide-based, polymer-based, or a mixture of both to obtain the desired properties.

[0317] Several peptide-based and polymer-based support molecules were tested, as listed in Table 1 below. Peptide-based support molecules carry a mixture of positively charged residues and neutral residues that allow nucleic acid complexing but also provide protection against nucleases. Polymer-based support molecules consist of poly-L-lysine (PPL) of various sizes and have a high complex success rate, but may have a reduced ability to protect nucleic acid cargo from nuclease degradation. In addition, PEG2000 was added to the N-terminus of Exc 1 (SEQ ID NO: 19) to form a hybrid support molecule (not shown in Table 1).

[0318] Table 1

[0319]

[0320] The amount of the support molecule for compounding and protecting the plasmid construct is determined by the N / P ratio, and its formula is disclosed herein. The higher the N / P ratio, the more support molecules there are in the final composition. Once the N / P ratio is determined, the support molecule and the plasmid solution can be merged. The solution is mixed with 10x phosphate buffered saline (PBS), and salt and nuclease-free water (NFW) that help compounding are provided to make up the total volume. The support molecule can be used with a DNA concentration of about 0.05 μg / μL to about 0.5 μg / μL. For example, in order to achieve an N / P ratio of 3 with a plasmid solution of 1.0 μg / μL and a support molecule solution (final DNA concentration of 0.5 μg / μL) of 1300 μg concentration of 5.0 μg / μL, 300 μL plasmid solution, 260 μL support molecule solution, 6 μL of 10x PBS and 34 μL of NFW are combined to reach a total volume of 600 μL. The solution is then mixed at room temperature at 300 rpm for 30 minutes.

[0321] To determine whether the support molecules successfully complexed with the plasmid nucleic acid, the final product was run on a 1.1% agarose gel to observe whether free plasmid was still present after the reaction. The results showed that Exc 1 showed partial complexation at N / P ratios of 1 or 2, but showed complete complexation at N / P ratios of 5 and 8. Exc 2 showed no complexation at N / P ratio of 1 and partial complexation at N / P ratio of 5, while Exc 3 showed no complexation at N / P ratios of 1 or 5. The polymer-based support molecules work at lower N / P ratios due to their consistent forward sequences. PLL P1, PLL P2, and PLL P3 all showed complete complexation at N / P ratios as low as 0.5. The hybrid PEG-Exc 1 support molecule showed complexation at N / P ratios similar to Exc 1 itself.

[0322] Nuclease protection was determined using a DNase I assay. The samples were subjected to 5U of DNase I (M030S, New England Biolabs) for 30 minutes at 37°C. This amount was determined by titrating the amount of DNase I required to completely degrade 0.5ug of plasmid (i.e., the maximum amount of DNA that can be processed by the removal kit). The samples were then purified using a commercially available kit (T1030L) from New England Biolabs. After removal, the samples were run on a 1.1% agarose gel to see if there was any remaining complex, plasmid, or both. Experiments were performed with Exc 1 complexed with plasmid DNA at N / P ratios of 5 and 8. As a control, 10 μg of DNA was removed from the sample and the transfection agent TurboFect was also included. TM (R0531, ThermoFisher Scientific) complexed plasmids because it also exhibited the ability to complex. Although all three solutions complexed with DNA plasmids, TurboFect TM The plasmid was not protected from degradation. Exc 1 showed little degradation at both N / P ratios. Other experiments with PPL support molecules showed that they had weaker DNase protection. The PEG-Exc 1 hybrid protected equally to Exc 1, indicating that PEG does not affect the stability of the support molecule.

[0323] To determine whether the PEG-Exc 1 hybrid support molecule causes any cytotoxicity, the treated mouse cells (C2C12, CRL-1772, ATCC) were subjected to CellTiter Luminescent cell viability assay (G7570, Promega). Cells were incubated with support molecule encapsulation conjugates (nanocarrier, plasmid, targeting moiety, and support molecule) at doses based on plasmid mass (0.2 μg and 1.0 μg / well). Samples were tested in quintuplicate. At 0.2 μg / well, PEG-Exc1 or TurboFect TM There was no statistical loss of viability. At 1.0 μg / well, PEG-Exc 1 and TurboFect TM Both affect vitality.

[0324] Additional support molecules can be designed. Modifying the number of H1 sequences can compress nucleic acids, and the N / P ratio and total stabilizer content can be reduced by their addition. Different CPPs such as arginine-8 can be added in in vitro and in vivo models to change transfection. Similarly, alternative NLS sequences can be studied to enhance nuclear delivery. In addition, peptide targeting sequences can be added to base stabilizers during synthesis, or can be chemically added (e.g., click chemistry, amides, cross-linking) through functional groups. Finally, specific regions of the support molecule can be made neutral or positive to perform local isolation of charge for compounding, and new functional groups can be added at the ends or distributed throughout the chain. For example, these can include binding sites for small molecules, antibodies, and peptide sequences.

Claims

1. A composition comprising a DNA dendrimer linked to or associated with: a targeting moiety; and Adapter molecule-cargo polynucleotide complex.

2. The composition of claim 1, wherein the DNA dendrimer is linked to the adapter molecule-cargo polynucleotide complex via electrostatic interactions, covalent bonds, non-covalent bonds, or hydrogen bonds with the adapter molecule.

3. The composition of claim 1 or 2, wherein the cargo polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one target molecule, wherein the cargo polynucleotide is a nicked circular polynucleotide, a linear polynucleotide having closed 5′ and 3′ ends, a linear polynucleotide having open 5′ and 3′ ends, or a linear polynucleotide having one open end and one closed end, wherein the one open end and the one closed end can be at the 5′ and 3′ of the polynucleotide.

4. The composition of claim 2, wherein the cargo polynucleotide further comprises at least one DNA targeting sequence (DTS).

5. The composition of claim 4, wherein the at least one DTS is located upstream of the at least one promoter.

6. The composition of claim 4, wherein the at least one DTS is located downstream of the at least one promoter.

7. The composition of any one of claims 4-6, wherein the cargo polynucleotide comprises two or more DTSs.

8. The composition of claim 7, wherein the two or more DTSs are positioned adjacent or substantially adjacent to each other.

9. The composition of claim 7, wherein the two or more DTSs are not positioned adjacent or substantially adjacent to each other.

10. The composition of any one of claims 1-5, wherein the cargo polynucleotide further comprises at least one nuclear localization signal sequence (NLS).

11. The composition of claim 10, wherein the at least one NLS is located upstream of the at least one promoter.

12. The composition of claim 10, wherein the at least one NLS is located downstream of the at least one promoter.

13. The composition of any one of claims 6-8, wherein the cargo polynucleotide comprises at least one DTS and at least one NLS.

14. The composition of any one of claims 1-9, wherein the adapter molecule comprises a DNA dendrimer binding sequence (DBS) and a cargo binding region (CBR).

15. The composition of claim 14, wherein the adaptor is linked to the DNA dendrimer via the DBS.

16. The composition of claim 14 or 15, wherein the DBS comprises a nucleic acid sequence complementary to a nucleic acid sequence on the DNA dendrimer.

17. The composition of any one of claims 14-16, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO: 3), CCTCAG CTTGTACTCTAGTTGTTACCTCTAATGCTGGACCTCAGC (SEQ ID NO: 22), or CCTCAGCACCCTACAGAGTAACCTAGATTGATCAA ACACCTCAGC (SEQ ID NO: 23).

18. The composition of any one of claims 14-17, wherein the DBS further comprises a polythymine sequence at the 5' or 3' end of the DBS.

19. The composition of claim 18, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTTT (SEQ ID NO: 4).

20. The composition of any one of claims 14-19, wherein the cargo binding region (CBR) is capable of being linked to the cargo polynucleotide via DNA ligation, i.e. linked to the polynucleotide via a covalent bond such as a phosphodiester bond.

21. The composition of any one of claims 14-19, wherein the CBR is capable of being linked to the cargo polynucleotide by chemical coupling, ie, linked to the polynucleotide by a covalent bond such as a disulfide bond.

22. The composition of any one of claims 14-21, wherein the cargo binding region comprises at least one cysteine.

23. The composition of any one of claims 14-22, wherein the adapter molecule further comprises a tag, such as a tag that can be used as an affinity tag to isolate / purify the composition complex.

24. The composition of claim 23, wherein the tag is located between the DBS and the CBR.

25. The composition of claim 24, wherein the tag is a polyhistidine tag.

26. The composition of any one of claims 14-25, wherein the adapter molecule further comprises at least one nuclear localization signal sequence (NLS).

27. The composition of claim 26, wherein the at least one NLS is located between or overlaps with the DBS and the cargo binding region.

28. The composition of claim 26 or 27, wherein the at least one NLS comprises one or more NLS sequences disclosed herein.

29. The composition of any one of claims 26-28, wherein the at least one NLS comprises the amino acid sequence of YPDEVKRKKKP (SEQ ID NO: 1).

30. The composition of any one of claims 26-28, wherein the at least one NLS comprises the amino acid sequence of SLLESPFDKPDEVKRKKKPPTSHQSDATAEDDSSSKK K (SEQ ID NO: 2).

31. The composition of any one of claims 26-30, wherein the at least one NLS further comprises at least one spacer located before or after the at least one NLS.

32. A composition as described in claim 31, wherein the at least one NLS comprises two spacers located before or after the at least one NLS, such as one spacer located before the NLS and one spacer located after the NLS, or two spacers located before or after the NLS.

33. The composition of claim 31 or 32, wherein the one or more spacers comprise polyethylene glycol (PEG), propylene glycol alginate (PGA), PEG-polylactic acid (PLA), polylactic-co-glycolic acid (PGLA), or any combination thereof.

34. A composition as described in claim 31 or 32, wherein the one or more spacers comprise a poly-glycine sequence, optionally with alanine and / or serine residues.

35. The composition of claim 34, wherein the one or more spacers have an amino acid sequence of GGGG (SEQ ID NO: 5).

36. The composition of any one of claims 14-35, wherein the adapter molecule further comprises at least one DNA targeting sequence (DTS).

37. The composition of claim 36, wherein the at least one DTS is located The DBS and the CBR overlap with each other or overlap with the DBS and the CBR.

38. The composition of any one of claims 14-37, wherein the adapter molecule further comprises a cell penetrating peptide sequence (CPP).

39. The composition of claim 38, wherein the CPP is located between or overlaps the DBS and the CBR.

40. The composition of claim 38 or 39, wherein the CPP comprises a CPP disclosed herein.

41. The composition of any one of claims 38-40, wherein the CPP comprises the amino acid sequence of QPRRRPRRKKRG (SEQ ID NO: 6).

42. The composition of any one of claims 14-41, wherein the adapter molecule further comprises at least one cleavage site.

43. The composition of claim 42, wherein the at least one cleavage site is located between or overlaps with the DBS and the CBR.

44. The composition of claim 42 or 43, wherein the cleavage site is located near the DBS.

45. A composition as described in any of claims 42-44, wherein the cleavage site is a val-cit linker.

46. ​​The composition of any one of claims 14-45, wherein the adapter molecule further comprises at least one flexible linker.

47. The composition of claim 46, wherein the at least one flexible linker is located between the DNS and the CBR.

48. The composition of claim 46 or 47, wherein the at least one flexible linker is selected from polyethylene glycol (PEG), propylene glycol alginate (PGA), PEG-polylactic acid (PLA), Polylactic acid-co-glycolic acid (PGLA), (GG)n, (GGGGS)n or (GGGGA)n, wherein each n is independently 1-5.

49. The composition of any one of claims 1-47, wherein the composition further comprises a support molecule.

50. The composition of claim 49, wherein the support molecule is attached to the DNA dendrimer.

51. The composition of claim 49, wherein the support molecule is not attached to the DNA dendrimer.

52. The composition of any one of claims 49-51, wherein the support molecule compacts the size of the cargo polynucleotide, the DNA dendrimer, or both.

53. A composition as described in any of claims 49-52, wherein the support molecule is capable of facilitating nuclear delivery.

54. The composition of any one of claims 49-53, wherein the support molecule is capable of protecting the cargo polynucleotide, the DNA dendrimer, or both from nuclease degradation.

55. The composition of any one of claims 49-54, wherein the support molecule is capable of enhancing the transfection efficiency of the composition.

56. The composition of any one of claims 49-55, wherein the support molecule comprises the amino acid sequence of ATPKKSTKKTPKKAKKATPKKSTKKTPKKKAKK (SEQ ID NO: 12), WRRRGFGRRR (SEQ ID NO: 13), GRKKRRQRRRPQ (SEQ ID NO: 14), PKKKRKV (SEQ ID NO: 15), GLFHAIAHFIHG GWHGLIHGWYG (SEQ ID NO: 16), WEAALAEALAEALAEHLA EALAEALEALAA (SEQ ID NO: 17), HHHHHHHHHH (SEQ ID NO: 18), (KK)q, wherein q is 2-15.

57. The composition of any one of claims 49-56, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVATPKK STKKTPKKAKKATPKKSTKKTPKKKAKK (SEQ ID NO: 19).

58. The composition of any one of claims 49-56, wherein the support molecule comprises the amino acid sequence of HHHHHHHHHHATPKKSTKKTPKKAKKATPKKSTKKTPKK AKK (SEQ ID NO: 20).

59. The composition of any one of claims 49-56, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVGRKKR RQRRRPQWRRRGFGRRR (SEQ ID NO: 21).

60. The composition of any one of claims 49-56, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKK (SEQ ID NO: 24).

61. The composition of any one of claims 49-56, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO:25).

62. The composition of any one of claims 49-56, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 26).

63. The composition of any one of claims 1-62, wherein the targeting moiety is selected from antibodies, naturally occurring ligands of receptors or functional derivatives thereof, vitamins, hormones, small molecule mimetics of naturally occurring ligands, peptides, polypeptides, peptide mimetics, carbohydrates, lipids, aptamers, nucleic acids, toxins, components of microorganisms, any other molecule, provided that it specifically binds to a cell surface molecule and induces endocytosis of the bound portion, or any combination thereof.

64. A composition comprising a cargo polynucleotide, a support molecule, and a DNA dendrimer linked to a targeting moiety.

65. compositions as claimed in claim 64, wherein said targeting moiety is selected from the group consisting of antibodies, naturally occurring ligands of receptors or their functional derivatives, vitamins, hormones, small molecule mimics of naturally occurring ligands, peptides, polypeptides, peptide mimics, carbohydrates, lipids, aptamers, nucleic acids, toxins, components of microorganisms, any other molecule, provided that it specifically binds to a cell surface molecule and induces endocytosis of the bound portion, or any combination thereof.

66. The composition of claim 64 or 65, wherein: The cargo polynucleotide comprises at least one promoter and at least one coding sequence encoding at least one target molecule, and optionally a DNA binding sequence (DBS), wherein the cargo polynucleotide is a complete circular polynucleotide (e.g., a plasmid), a nicked circular polynucleotide, a linear polynucleotide with closed 5′ and 3′ ends, a linear polynucleotide with open 5′ and 3′ ends, or a linear polynucleotide with one open end and one closed end, Wherein the one open end and the one closed end can be at 5' and 3' of the cargo polynucleotide.

67. The composition of claim 66, wherein the cargo polynucleotide is a closed circular polynucleotide.

68. The composition of claim 66, wherein the cargo polynucleotide is a nicked circular polynucleotide.

69. The composition of any one of claims 64-68, wherein the cargo polynucleotide is not covalently linked to the DNA dendrimer.

70. The composition of any one of claims 64-69, wherein the carrier The polynucleotide also comprises at least one DNA targeting sequence (DTS).

71. The composition of claim 70, wherein the DTS is located within the cargo polynucleotide.

72. The composition of claim 70, wherein the DTS is linked to the cargo polynucleotide.

73. The composition of claim 72, wherein the cargo polynucleotide is a nicked circular polynucleotide and the DTS is linked to the cargo polynucleotide at the single-stranded DNA break (ie, the location of the nick).

74. The composition of any one of claims 64-73, wherein the cargo polynucleotide further comprises at least one nuclear localization signal sequence (NLS).

75. The composition of any one of claims 64-74, wherein the cargo polynucleotide comprises at least one DTS and at least one NLS.

76. The composition of any one of claims 66-75, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO: 3), CCTCAG CTTGTACTCTAGTTGTTACCTCTAATGCTGGACCTCAGC (SEQ ID NO: 22), or CCTCAGCACCCTACAGAGTAACCTAGATTGATCAA ACACCTCAGC (SEQ ID NO: 23).

77. The composition of claim 76, wherein the DBS further comprises a polythymine sequence at the 5' or 3' end of the DBS.

78. The composition of claim 77, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTT (SEQ ID NO: 4).

79. The composition of any one of claims 64-78, wherein the support molecule is attached to the DNA dendrimer.

80. The composition of any one of claims 64-79, wherein the support molecule is not attached to the DNA dendrimer.

81. The composition of any one of claims 64-80, wherein the support molecule compacts the size of the cargo polynucleotide, the DNA dendrimer, or both.

82. A composition as described in any one of claims 64-81, wherein the support molecule is capable of facilitating nuclear delivery.

83. The composition of any one of claims 64-82, wherein the support molecule is capable of protecting the cargo polynucleotide, the DNA dendrimer, or both from nuclease degradation.

84. A composition as described in any one of claims 64-83, wherein the support molecule is capable of enhancing the transfection efficiency of the composition.

85. The composition of any one of claims 64-84, wherein the presence of the support molecule facilitates the association of the cargo polynucleotide and the DNA dendrimer with each other.

86. A composition as described in any of claims 64-85, wherein the support molecule has a positive charge.

87. The composition of any one of claims 64-86, wherein the support molecule comprises an amino acid sequence of ATPKKSTKKTPKKAKKATPKKSTKKTPKKAKK (SEQ ID NO: 12), WRRRGFGRRR (SEQ ID NO: 13), GRKKRRQRRRPQ (SEQ ID NO: 14), PKKKRKV (SEQ ID NO: 15), GLFHAIAHFIHG GWHGLIHGWYG (SEQ ID NO: 16), WEAALAEALAEALAEHLA EALAEALEALAA (SEQ ID NO: 17), HHHHHHHHHH (SEQ ID NO: 18), (KK)q, or any combination thereof, wherein q is 2-15.

88. The composition of any one of claims 64-87, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVATPKK STKKTPKKAKKATPKKSTKKTPKKKAKK (SEQ ID NO: 19).

89. The composition of any one of claims 64-87, wherein the support molecule comprises the amino acid sequence of HHHHHHHHHHATPKKSTKKTPKKAKKATPKKSTKKTPKK AKK (SEQ ID NO: 20).

90. The composition of any one of claims 64-87, wherein the support molecule comprises the amino acid sequence of GLFHAIAHFIHGGWHGLIHGWYGWSQPPKKKRKVGRKKR RQRRRPQWRRRGFGRRR (SEQ ID NO: 21).

91. The composition of any one of claims 64-87, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKK (SEQ ID NO:24).

92. The composition of any one of claims 64-87, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO:25).

93. The composition of any one of claims 64-87, wherein the support molecule comprises the amino acid sequence of KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 26).

94. The composition of any one of claims 64-93, wherein the support molecule further comprises a polyethylene glycol (PEG) molecule attached to the support molecule.

95. The composition of claim 94, wherein the polyethylene molecule is PEG2000.

96. The composition of claim 94 or 95, wherein the PEG molecule is attached to the N-terminus of the support molecule.

97. The composition of any one of claims 1-97, wherein the coding sequence of the cargo polynucleotide encodes an antibody, an enzyme, a protein, a miRNA, a siRNA, an antisense RNA, etc.

98. The composition of any one of claims 1-97, wherein the nitrogen / phosphate (N / P) ratio of the composition is between 0.5 and 10.

99. The composition of claim 98, wherein the N / P ratio of the composition is between 2 and 5.

100. A pharmaceutical composition comprising the composition of any one of claims 1-99 and a pharmaceutically acceptable carrier.

101. A method of delivering a target molecule to the nucleus of a target cell, the method comprising contacting the target cell with a composition as described in any one of claims 1-99 or a pharmaceutical composition as described in claim 100, wherein the targeting moiety binds to the target cell.

102. The method of claim 101, wherein the cargo polynucleotide expresses the molecule of interest in the nucleus of the target cell.

103. The method of claim 101 or 102, wherein the cargo polynucleotide expresses two or more target molecules in the nucleus of the target cell.

104. The method of any one of claims 101-103, wherein the cargo polynucleotide comprises a tissue-specific promoter.

105. The method of any one of claims 101-104, wherein the targeting moiety is a tissue-specific targeting moiety.

106. The method of any one of claims 101-105, wherein the composition or pharmaceutical composition comprises two or more targeting moieties.

107. A method of treating a disease, the method comprising administering the composition of any one of claims 1-99 or the pharmaceutical composition of claim 100 to a subject to treat the disease, wherein the targeting moiety binds to the target cell.

108. The method of claim 107, wherein the cargo polynucleotide expresses the molecule of interest in the nucleus of the target cell.

109. The method of claim 107 or 108, wherein the cargo polynucleotide expresses two or more molecules of interest in the nucleus of the target cell.

110. The method of any one of claims 107-109, wherein the cargo polynucleotide comprises a tissue-specific promoter.

111. The method of any one of claims 107-110, wherein the targeting moiety is a tissue-specific targeting moiety.

112. The method of any one of claims 107-111, wherein the composition or pharmaceutical composition comprises two or more targeting moieties.

113. A plasmid comprising a plasmid backbone comprising at least two enzyme restriction recognition sites, at least one promoter, at least one coding sequence encoding at least one target molecule and optionally a DNA dendrimer binding sequence (DBS), wherein the plasmid is capable of forming a cargo polynucleotide having various structures depending on whether the plasmid has one or more of a 5′ end and a 3′ end or has no such ends.

114. A plasmid as described in claim 113, wherein the plasmid is a complete circular polynucleotide, a nicked circular polynucleotide, a linear polynucleotide with closed 5' and 3' ends, a linear polynucleotide with open 5' and 3' ends, and a linear polynucleotide with one open end and one closed end.

115. A plasmid as described in claim 113, wherein the nicked circular nucleotides, linear nucleotides with closed 5' and 3' ends, linear nucleotides with open 5' and 3' ends, and linear nucleotides with one open end and one closed end are formed by cutting the plasmid with one or more restriction enzymes.

116. The plasmid of any one of claims 113-115, wherein the plasmid further comprises at least one DNA targeting sequence (DTS).

117. The plasmid of claim 116, wherein the at least one DTS is located in the plasmid backbone, i.e., between or overlapping the at least two enzyme restriction recognition sites.

118. The plasmid of claim 116 or 117, wherein the at least one DTS is located upstream of the at least one promoter.

119. The plasmid of claim 116 or 117, wherein the at least one DTS is located downstream of the at least one promoter.

120. The plasmid of any one of claims 113-119, wherein the cargo polynucleotide further comprises at least one nuclear localization signal sequence (NLS).

121. The plasmid of claim 120, wherein the at least one NLS is located upstream of the at least one promoter.

122. The plasmid of claim 120, wherein the at least one NLS is located downstream of the at least one promoter.

123. The plasmid of any one of claims 116-122, wherein the cargo polynucleotide comprises at least one DTS and at least one NLS.

124. The composition of any one of claims 116-123, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAA (SEQ ID NO: 3), CCTCAGCTTGTACTCTAGTTGTTACCTCTAATGCTGGACCTCAGC (SEQ ID NO: 22), or CCTCAGCACCCTACAGAGTAACCTAGATTGATC AAACACCTCAGC (SEQ ID NO: 23).

125. The composition of claim 124, wherein the DBS further comprises a polythymidine sequence at the 5' or 3' end of the DBS.

126. The composition of claim 125, wherein the DBS comprises a nucleic acid sequence of TAGAGGTAACAACTAGCGTACAATTTTTTTTTTT (SEQ ID NO: 4).

127. A plasmid as described in any one of claims 116-126, wherein the at least one promoter is a tissue-specific promoter.

128. The plasmid of any one of claims 116-126, wherein the plasmid comprises a polynucleotide sequence encoding two or more molecules of interest.

129. A method of making a composition as described in any one of claims 1-63, comprising: contacting the plasmid of any one of claims 113 to 129 with one or more restriction enzymes that cleave at the restriction enzyme recognition site to form a nicked circular polynucleotide, a linear polynucleotide with closed 5′ and 3′ ends, a linear polynucleotide with open 5′ and 3′ ends, or a linear polynucleotide with one open end and one closed end, ligating the cargo polynucleotide to the adapter molecule to form an adapter molecule-cargo polynucleotide complex, and The adapter molecule-cargo polynucleotide complex and the targeting moiety are linked to a DNA dendrimer to form the composition.

130. A method of making a composition as described in any one of claims 64-99, comprising: contacting a plasmid as claimed in any one of claims 113 to 129 comprising a DNA dendrimer binding sequence (DBS) with one or more restriction enzymes which cleave at the restriction enzyme recognition site to form a nicked circular polynucleotide, a linear polynucleotide with closed 5′ and 3′ ends, a linear polynucleotide with open 5′ and 3′ ends, or a linear polynucleotide with one open end and one closed end, and The cargo polynucleotide and targeting moiety are linked to a DNA dendrimer to form the composition.

131. A method for making a composition as described in any one of claims 64-99, comprising The circular uncut plasmid of any one of claims 113-129 having a DNA dendrimer attached to a targeting moiety is contacted with a support molecule capable of compacting the size of the cargo polynucleotide and the DNA dendrimer such that the cargo polynucleotide and the DNA dendrimer associate together to form the composition.

132. A kit comprising the composition of claims 1-99, the pharmaceutical composition of claim 100, the plasmid of any one of claims 113-129, or a combination thereof.